

Reliability and validity of the positive and negative syn

Psychiatry Research

23, 99-110

DOI: 10.1016/0165-1781(88)90038-8

Citation Report

#	ARTICLE	IF	CITATIONS
1	The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia. <i>Schizophrenia Bulletin</i> , 1987, 13, 261-276.	2.3	17,788
2	The Positive and Negative Syndrome Scale (PANSS): Rationale and Standardisation. <i>British Journal of Psychiatry</i> , 1989, 155, 59-65.	1.7	863
3	Depression, Affect and Negative Symptoms in Schizophrenia. <i>British Journal of Psychiatry</i> , 1989, 155, 108-114.	1.7	33
4	The Positive-Negative Distinction in Drug-Free Schizophrenic Patients. <i>Archives of General Psychiatry</i> , 1989, 46, 711.	13.8	127
5	Positive-negative symptom assessment in schizophrenia: Psychometric issues and scale comparison. <i>Psychiatric Quarterly</i> , 1990, 61, 163-178.	1.1	115
6	The brief psychiatric rating scale (BPRS) and the nurses' observation scale for inpatient evaluation (NOSIE) in the evaluation of positive and negative symptoms. <i>Journal of Clinical Psychology</i> , 1990, 46, 168-174.	1.0	17
7	Significance of the Positive-negative Distinction in Schizophrenia. <i>Schizophrenia Bulletin</i> , 1990, 16, 635-652.	2.3	66
8	Pyramidal Model of Schizophrenia. <i>Schizophrenia Bulletin</i> , 1990, 16, 537-545.	2.3	417
9	Neurological signs and the positive-negative dimension in schizophrenia. <i>Biological Psychiatry</i> , 1990, 28, 181-192.	0.7	100
10	Predicting outcome of schizophrenia: Significance of symptom profiles and outcome dimensions. <i>Comprehensive Psychiatry</i> , 1990, 31, 91-102.	1.5	41
11	Schizophrenic patients with depression: Psychopathological profiles and relationship with negative symptoms. <i>Comprehensive Psychiatry</i> , 1991, 32, 528-533.	1.5	42
12	Stability of psychopathology dimensions in chronic schizophrenia: Response to clozapine treatment. <i>Comprehensive Psychiatry</i> , 1991, 32, 28-35.	1.5	8
13	SCID-PANSS: Two-tier diagnostic system for psychotic disorders. <i>Comprehensive Psychiatry</i> , 1991, 32, 355-361.	1.5	69
14	Olfactory acuity in the positive and negative syndromes of schizophrenia. <i>Biological Psychiatry</i> , 1991, 29, 774-778.	0.7	39
15	The MCPP challenge test in schizophrenia: Hormonal and behavioral responses. <i>Biological Psychiatry</i> , 1991, 30, 770-778.	0.7	67
16	Principal-component analysis of PANSS and SANS - SAPS global ratings in schizophrenic patients. <i>European Psychiatry</i> , 1991, 6, 251-259.	0.1	36
17	Reliability and validity of the Chinese versions of the Scales for Assessment of Positive and Negative Symptoms. <i>Acta Psychiatrica Scandinavica</i> , 1991, 84, 364-370.	2.2	78
18	Atrophy of the Cerebellar Vermis: Relevance to the Symptoms of Schizophrenia. <i>International Journal of Neuroscience</i> , 1991, 57, 205-212.	0.8	37

#	ARTICLE	IF	CITATIONS
19	Neuroradiological Facets of Cognitive Abnormality in Schizophrenia. <i>International Journal of Neuroscience</i> , 1991, 58, 83-93.	0.8	5
20	Experimental Models of Schizophrenia. <i>International Journal of Neuroscience</i> , 1991, 58, 69-82.	0.8	16
21	Neuroradiological Covariates of Drug-Induced Parkinsonism and Tardive Dyskinesia in Schizophrenia. <i>International Journal of Neuroscience</i> , 1991, 58, 7-53.	0.8	6
22	Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. <i>Acta Psychiatrica Scandinavica</i> , 1992, 85, 295-305.	2.2	290
23	Ventricular enlargement, clinical correlates and treatment outcome in chronic schizophrenic inpatients. <i>Acta Psychiatrica Scandinavica</i> , 1992, 85, 306-312.	2.2	20
24	The Swedish version of the Positive and Negative Syndrome Scale (PANSS) for schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 1992, 86, 463-468.	2.2	59
25	The Pineal Gland and the Mode of Onset of Schizophrenia. <i>International Journal of Neuroscience</i> , 1992, 67, 9-17.	0.8	18
26	Multivalent assessment of depression in schizophrenia. <i>Psychiatry Research</i> , 1992, 42, 199-207.	1.7	14
27	Schneiderian symptoms and childhood trauma in the general population. <i>Comprehensive Psychiatry</i> , 1992, 33, 269-273.	1.5	90
28	Dimensions of Outcome with Clozapine. <i>British Journal of Psychiatry</i> , 1992, 160, 46-53.	1.7	225
29	Relationship between depressive and positive symptoms in schizophrenia. <i>Journal of Affective Disorders</i> , 1993, 28, 61-69.	2.0	34
30	Influence of renal clearance on peripheral homovanillic acid measurements in healthy subjects and schizophrenic patients. <i>Schizophrenia Research</i> , 1993, 11, 33-40.	1.1	13
31	A placebo-controlled trial of selegiline (l-deprenyl) in the treatment of tardive dyskinesia. <i>Biological Psychiatry</i> , 1993, 33, 700-706.	0.7	35
32	Aggressive Behavior in Schizophrenia: Relationship to Age of Onset and Cortical Atrophy. <i>International Journal of Neuroscience</i> , 1993, 68, 1-10.	0.8	10
33	Biological Determinants and Risk Factors for Tardive Dyskinesia in Schizophrenia. <i>International Journal of Neuroscience</i> , 1993, 69, 35-51.	0.8	4
34	Third Ventricular Width and its Relationship to Mode of Onset of Schizophrenia. <i>International Journal of Neuroscience</i> , 1993, 69, 119-124.	0.8	2
36	Reliability of a standardized and expanded Brief Psychiatric Rating Scale: a replication study. <i>Acta Psychiatrica Scandinavica</i> , 1993, 88, 305-310.	2.2	38
37	Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. <i>Acta Psychiatrica Scandinavica</i> , 1993, 88, 395-402.	2.2	170

#	ARTICLE	IF	CITATIONS
38	Risperidone in the treatment of schizophrenia. <i>American Journal of Psychiatry</i> , 1994, 151, 825-835.	4.0	1,179
39	Psychometric properties of the Positive and Negative Syndrome Scale (PANSS) in schizophrenia. <i>Psychiatry Research</i> , 1994, 53, 31-40.	1.7	471
40	A latent structure analysis of the positive and negative symptoms in schizophrenia. <i>Comprehensive Psychiatry</i> , 1994, 35, 252-259.	1.5	60
41	Psychopharmacologic treatment of negative schizophrenic symptoms. <i>Comprehensive Psychiatry</i> , 1994, 35, 16-28.	1.5	20
42	Testing Liddle's three-syndrome model in families with schizophrenia. <i>Schizophrenia Research</i> , 1994, 12, 213-221.	1.1	24
43	Interrater reliability of the Structured Clinical Interview for the Positive and Negative Syndrome Scale for schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 1994, 89, 192-195.	2.2	55
44	Positive and negative symptoms/syndromes in schizophrenia: reliability and validity of different diagnostic systems. <i>Psychological Medicine</i> , 1995, 25, 43-50.	2.7	51
45	Risperidone: Review and Assessment of Its Role in the Treatment of Schizophrenia. <i>Annals of Pharmacotherapy</i> , 1995, 29, 610-618.	0.9	26
46	Correlations between the Clinical Picture and the Intentionality in Schizophrenic and Schizoaffective Patients. <i>Psychopathology</i> , 1995, 28, 168-172.	1.1	1
47	Principal components and further possibilities with the PANSS. <i>Acta Psychiatrica Scandinavica</i> , 1995, 92, 5-10.	2.2	53
48	Cerebral ventricular enlargement and neuroleptic response in chronic schizophrenia: Preliminary findings with risperidone. <i>Human Psychopharmacology</i> , 1995, 10, 53-58.	0.7	3
49	Differential effects of the D1-DA receptor antagonist SCH39166 on positive and negative symptoms of schizophrenia. <i>Psychopharmacology</i> , 1995, 121, 317-322.	1.5	89
50	NNC 01-0687, a selective dopamine D1 receptor antagonist, in the treatment of schizophrenia. <i>Psychopharmacology</i> , 1995, 121, 328-329.	1.5	51
51	Risperidone in the Treatment of Patients with Chronic Schizophrenia: a Multi-National, Multi-Centre, Double-Blind, Parallel-Group Study versus Haloperidol. <i>British Journal of Psychiatry</i> , 1995, 166, 712-726.	1.7	567
52	Neurological soft signs in schizophrenia: Are they related to negative or positive symptoms, neuropsychological performance, and violence?. <i>Archives of Clinical Neuropsychology</i> , 1995, 10, 489-509.	0.3	19
53	Neuropsychological Correlates of Violence in Schizophrenia. <i>Schizophrenia Bulletin</i> , 1995, 21, 253-262.	2.3	42
54	Case Study: Risperidone in Children and Adolescents with Schizophrenia. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 1995, 34, 1292-1296.	0.3	67
55	Neurological soft signs in schizophrenia: Are they related to negative or positive symptoms, neuropsychological performance, and violence?. <i>Archives of Clinical Neuropsychology</i> , 1995, 10, 489-509.	0.3	16

#	ARTICLE	IF	CITATIONS
56	A study of the interrelationship between and comparative interrater reliability of the SAPS, SANS and PANSS. <i>Schizophrenia Research</i> , 1996, 19, 73-85.	1.1	106
57	A comparison of instrument sensitivity to negative symptom change. <i>Psychiatry Research</i> , 1996, 63, 67-75.	1.7	25
58	Delayed habituation of the skin-conductance orienting response correlates with impaired performance on the wisconsin card sorting task in schizophrenia. <i>Psychiatry Research</i> , 1996, 65, 107-112.	1.7	13
59	Adjunctive Antidepressant Drug Therapies in the Treatment of Negative Symptoms of Schizophrenia. <i>CNS Drugs</i> , 1996, 6, 130-147.	2.7	39
60	The Treatment of Negative Symptoms: Pharmacological and Methodological Issues. <i>British Journal of Psychiatry</i> , 1996, 168, 17-22.	1.7	33
61	Neurological soft signs in schizophrenia: Assessment and correlates. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1996, 246, 240-248.	1.8	97
62	Positive and Negative Symptoms: Is Their Change Related?. <i>Schizophrenia Bulletin</i> , 1996, 22, 577-590.	2.3	21
63	A Neuropsychological Study of Prefrontal Lobe Function in the Positive and Negative Subtypes of Schizophrenia. <i>Journal of Genetic Psychology</i> , 1997, 158, 487-494.	0.6	26
64	Attribution Therapy for Paranoid Delusions: A Case Study. <i>Behavioural and Cognitive Psychotherapy</i> , 1997, 25, 269-280.	0.9	14
65	Neurocognitive Correlates of Positive and Negative Syndromes in Schizophrenia. <i>Canadian Journal of Psychiatry</i> , 1997, 42, 1066-1071.	0.9	90
66	Neurocognitive deficits and neurological signs in schizophrenia. <i>Schizophrenia Research</i> , 1997, 23, 139-146.	1.1	72
67	Are there gender differences in neuropsychological performance in patients with first-episode schizophrenia?. <i>Schizophrenia Research</i> , 1997, 28, 39-50.	1.1	61
68	Measuring quality of life in schizophrenia. <i>European Psychiatry</i> , 1997, 12, 267s-274s.	0.1	53
69	Pramipexole as adjunct to haloperidol in schizophrenia. <i>European Neuropsychopharmacology</i> , 1997, 7, 65-70.	0.3	33
70	A new method for assessing interexaminer agreement when multiple ratings are made on a single subject: applications to the assessment of neuropsychiatric symptomatology. <i>Psychiatry Research</i> , 1997, 72, 51-63.	1.7	34
71	The Use of Scales for Clinical Monitoring of Disease Progression and the Treatment of Schizophrenia. <i>Neuropsychobiology</i> , 1997, 35, 64-66.	0.9	1
72	Improvement of inter-rater reliability of PANSS items and subscales by a standardized rater training. <i>Acta Psychiatrica Scandinavica</i> , 1998, 98, 135-139.	2.2	51
73	Neuropsychological impairment and psychopathology in first-episode schizophrenic patients related to the early course of illness. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1998, 248, 70-77.	1.8	38

#	ARTICLE	IF	CITATIONS
74	The structure of schizophrenic symptoms: a meta-analytic confirmatory factor analysis. <i>Schizophrenia Research</i> , 1998, 31, 57-70.	1.1	69
75	Evaluation of standardized rater training for the Positive and Negative Syndrome Scale (PANSS). <i>Schizophrenia Research</i> , 1998, 32, 151-160.	1.1	46
76	Combined clozapine-lithium treatment for schizophrenia and schizoaffective disorder. <i>European Psychiatry</i> , 1998, 13, 104-106.	0.1	16
77	Measures of anhedonia and hedonic responses to sucrose in depressive and schizophrenic patients in comparison with healthy subjects. <i>European Psychiatry</i> , 1998, 13, 303-309.	0.1	147
78	Comprehension of irony in Schizophrenia. <i>Cognitive Neuropsychiatry</i> , 1998, 3, 127-138.	0.7	87
79	Word and Tone Working Memory Deficits in Schizophrenia. <i>Archives of General Psychiatry</i> , 1998, 55, 1093.	13.8	143
80	A Typical Children Followed-Up in Adolescence. <i>Clinical Child Psychology and Psychiatry</i> , 1998, 3, 289-303.	0.8	0
81	Negative Symptoms in Schizophrenia: Neurobiological Models and Treatment Response. <i>Harvard Review of Psychiatry</i> , 1998, 6, 59-77.	0.9	57
82	Risperidone Versus Clozapine in Treatment-Resistant Chronic Schizophrenia: A Randomized Double-Blind Study. <i>American Journal of Psychiatry</i> , 1998, 155, 499-504.	4.0	266
83	Interrater reliability of the Japanese version of the Positive and Negative Syndrome Scale and the appraisal of its training effect. <i>Psychiatry and Clinical Neurosciences</i> , 1998, 52, 467-470.	1.0	61
84	An approach to treatment resistance in schizophrenia. <i>British Journal of Psychiatry</i> , 1999, 174, 19-22.	1.7	7
85	Atypical Antipsychotics Part I: Pharmacology, Pharmacokinetics, and Efficacy. <i>Annals of Pharmacotherapy</i> , 1999, 33, 73-85.	0.9	195
86	Auditory event-related potentials and clinical scores in unmedicated schizophrenic patients. <i>Psychiatry Research</i> , 1999, 86, 229-238.	1.7	56
87	Choosing negative symptom instruments: issues of representation and redundancy. <i>Psychiatry Research</i> , 1999, 87, 47-56.	1.7	26
88	Attentional deficits in patients with schizophrenia and in their non-psychotic first-degree relatives. <i>Psychiatry Research</i> , 1999, 89, 147-159.	1.7	89
89	A Rating Scale for Psychotic Symptoms (RSPS). <i>Schizophrenia Research</i> , 1999, 38, 101-122.	1.1	28
90	Hope, quality of life, and symptom severity in individuals with schizophrenia.. <i>Psychiatric Rehabilitation Journal</i> , 2000, 23, 364-369.	0.8	61
91	Ritanserin as add-on medication to neuroleptic therapy for patients with chronic or subchronic schizophrenia. , 2000, 15, 179-189.		33

#	ARTICLE	IF	CITATIONS
92	A 1-Year Cost-Effectiveness Model for the Treatment of Chronic Schizophrenia with Acute Exacerbations in Belgium. <i>Value in Health</i> , 2000, 3, 1-11.	0.1	23
93	Use of quantitative rating scales to assess outcome in schizophrenia prevention studies. <i>Australian and New Zealand Journal of Psychiatry</i> , 2000, 34, S150-S160.	1.3	1
94	Outcome of schizophrenia in a non-industrialized society: comparative study between Bali and Tokyo. <i>Acta Psychiatrica Scandinavica</i> , 2000, 101, 148-152.	2.2	18
95	Pharmacist-Designed and -Implemented Pharmaceutical Care Plan for Antipsychotic-Induced Movement Disorders. <i>Pharmacotherapy</i> , 2000, 20, 583-588.	1.2	11
97	Research Units on Pediatric Psychopharmacology (Rupp) Autism Network. <i>Child and Adolescent Psychiatric Clinics of North America</i> , 2000, 9, 201-224.	1.0	104
98	Use of Quantitative Rating Scales to Assess Outcome in Schizophrenia Prevention Studies. <i>Australian and New Zealand Journal of Psychiatry</i> , 2000, 34, A150-A160.	1.3	2
99	Altered Hemispheric Functional Dominance During Word Generation in Negative Schizophrenia. <i>Schizophrenia Bulletin</i> , 2000, 26, 709-721.	2.3	99
100	Use of Quantitative Rating Scales to Assess Outcome in Schizophrenia Prevention Studies. <i>Australian and New Zealand Journal of Psychiatry</i> , 2000, 34, S150-S160.	1.3	2
101	EEG Hemispheric Asymmetry as a Predictor and Correlate of Short-term Response to Clozapine Treatment in Schizophrenia. <i>Clinical EEG (electroencephalography)</i> , 2000, 31, 145-152.	0.9	19
102	Overlapping and Distinctive Features of Hypochondriasis and Obsessive-Compulsive Disorder. <i>Journal of Anxiety Disorders</i> , 2000, 14, 603-614.	1.5	40
103	Assessing Health Utilities in Schizophrenia. <i>Pharmacoeconomics</i> , 2000, 17, 273-286.	1.7	34
104	The efficacy of zotepine in treating acute negative symptoms of schizophrenia: The results of a meta-analysis. <i>International Journal of Psychiatry in Clinical Practice</i> , 2000, 4, 209-214.	1.2	1
105	Executive/attentional performance and measures of schizotypy in patients with schizophrenia and in their nonpsychotic first-degree relatives. <i>Schizophrenia Research</i> , 2000, 46, 269-283.	1.1	132
106	Quantitative EEG in schizophrenia and in response to acute and chronic clozapine treatment. <i>Schizophrenia Research</i> , 2001, 50, 41-53.	1.1	82
107	WCST performance and schizotypal features in the first-degree relatives of patients with schizophrenia. <i>Psychiatry Research</i> , 2001, 104, 133-144.	1.7	29
108	In Vivo Extrastriatal and Striatal D2 Dopamine Receptor Blockade by Amisulpride in Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2001, 21, 207-214.	0.7	89
109	Olanzapine for Schizophrenia Refractory to Typical and Atypical Antipsychotics: An Open-Label, Prospective Trial. <i>Journal of Clinical Psychopharmacology</i> , 2001, 21, 448-453.	0.7	31
110	Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind study. <i>International Clinical Psychopharmacology</i> , 2001, 16, 325-330.	0.9	48

#	ARTICLE	IF	CITATIONS
111	Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. <i>Psychopharmacology</i> , 2001, 153, 238-243.	1.5	112
112	Working memory in schizophrenia and mania: correlation with symptoms during the acute and subacute phases. <i>Acta Psychiatrica Scandinavica</i> , 2001, 103, 181-188.	2.2	74
113	Symptom severity and personal functioning among patients with schizophrenia discharged from long-term hospital care into the community. , 2001, 37, 145-155.		13
114	Chronic psychiatric status and satisfaction with life. <i>Personality and Individual Differences</i> , 2001, 31, 145-155.	1.6	26
115	Cost-utility of risperidone compared with standard conventional antipsychotics in chronic schizophrenia. <i>Journal of Medical Economics</i> , 2001, 4, 137-156.	1.0	24
116	INVESTIGATING THE CRITERION VALIDITY OF PSYCHIATRIC SYMPTOM SCALES USING SURROGATE MARKER VALIDATION METHODOLOGY. <i>Journal of Biopharmaceutical Statistics</i> , 2002, 12, 161-178.	0.4	22
117	The development and implementation of an individualised early signs monitoring system in the prediction of relapse in schizophrenia. <i>Journal of Mental Health</i> , 2002, 11, 141-153.	1.0	45
118	Clinical Outcome of Patients With Schizophrenia Without Maintenance Treatment in a Nonindustrialized Society. <i>Schizophrenia Bulletin</i> , 2002, 28, 515-524.	2.3	11
119	Clozapine, Olanzapine, Risperidone, and Haloperidol in the Treatment of Patients With Chronic Schizophrenia and Schizoaffective Disorder. <i>American Journal of Psychiatry</i> , 2002, 159, 255-262.	4.0	377
120	Temporal Lobe Abnormalities in First-Episode Psychosis. <i>American Journal of Psychiatry</i> , 2002, 159, 1232-1235.	4.0	85
121	RELATIONSHIP BETWEEN TOBACCO SMOKING AND POSITIVE AND NEGATIVE SYMPTOMS IN SCHIZOPHRENIA. <i>Journal of Nervous and Mental Disease</i> , 2002, 190, 604-610.	0.5	98
122	EEG coherence following acute and chronic clozapine in treatment-resistant schizophrenics.. <i>Experimental and Clinical Psychopharmacology</i> , 2002, 10, 435-444.	1.3	18
123	Antipsychotic Drug Treatment in the Prodromal Phase of Schizophrenia. <i>American Journal of Psychiatry</i> , 2002, 159, 1230-1232.	4.0	40
124	Would a Switch From Typical Antipsychotics to Risperidone Be Beneficial for Elderly Schizophrenic Patients? A Naturalistic, Long-Term, Retrospective, Comparative Study. <i>Journal of Clinical Psychopharmacology</i> , 2002, 22, 115-120.	0.7	43
125	Case Series: Use of Ziprasidone for Maladaptive Symptoms in Youths With Autism. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2002, 41, 921-927.	0.3	170
126	Proper Names and Noun-to-Determiner Movement in Aphasia: A Case Study. <i>Brain and Cognition</i> , 2002, 48, 542-545.	0.8	4
127	Validation of the Computerized Suicide Risk Scale " a backpropagation neural network instrument (CSRS-BP). <i>European Psychiatry</i> , 2002, 17, 75-81.	0.1	13
128	The impact of side-effects of antipsychotic agents on life satisfaction of schizophrenia patients: a naturalistic study. <i>European Neuropsychopharmacology</i> , 2002, 12, 31-38.	0.3	93

#	ARTICLE	IF	CITATIONS
129	Validation study of PECC (Psychosis Evaluation tool for Common use by Caregivers): Interscale validity and inter-rater reliability. <i>International Journal of Psychiatry in Clinical Practice</i> , 2002, 6, 135-140.	1.2	38
130	A three-year naturalistic follow-up of patients receiving clozapine: Report from India. <i>International Journal of Psychiatry in Clinical Practice</i> , 2002, 6, 167-171.	1.2	14
131	Working memory correlates of three symptom clusters in schizophrenia. <i>Psychiatry Research</i> , 2002, 110, 49-61.	1.7	81
132	Is There a Gender Difference in a Factorial Structure of the Positive and Negative Syndrome Scale?. <i>Psychopathology</i> , 2002, 35, 28-35.	1.1	26
133	Behavioral Disorganization in Schizophrenia during a Daily Activity: The Kitchen Behavioral Scoring Scale. <i>Brain and Cognition</i> , 2002, 48, 546-553.	0.8	21
134	Statistical challenges in the evaluation of surrogate endpoints in randomized trials. <i>Contemporary Clinical Trials</i> , 2002, 23, 607-625.	2.0	108
135	Validity and reliability of the Polish version of the Positive and Negative Syndrome Scale (PANSS). <i>International Journal of Methods in Psychiatric Research</i> , 2002, 11, 27-32.	1.1	27
136	Itemized clinician ratings versus global ratings of symptom severity in patients with schizophrenia. <i>International Journal of Methods in Psychiatric Research</i> , 2002, 11, 45-53.	1.1	3
137	Validation of Surrogate Endpoints in Multiple Randomized Clinical Trials with Discrete Outcomes. <i>Biometrical Journal</i> , 2002, 44, 921-935.	0.6	44
138	A pharmacoeconomic evaluation of zuclopenthixol compared with haloperidol and risperidone in the treatment of schizophrenia. <i>European Journal of Health Economics</i> , 2002, 3, 173-179.	1.4	6
139	Effects of group musical therapy on inpatients with chronic psychoses: A controlled study. <i>Psychiatry and Clinical Neurosciences</i> , 2002, 56, 187-193.	1.0	59
140	Moderators of placebo response to antipsychotic treatment in patients with schizophrenia: a meta-regression. <i>Psychopharmacology</i> , 2003, 166, 1-10.	1.5	34
141	Effect of nizatidine on olanzapine-associated weight gain in schizophrenic patients in Korea: a pilot study. <i>Human Psychopharmacology</i> , 2003, 18, 453-456.	0.7	15
142	The factor structure for the Positive and Negative Syndrome Scale (PANSS) in recent-onset psychosis. <i>Schizophrenia Research</i> , 2003, 61, 47-57.	1.1	329
143	The InterSePT scale for suicidal thinking reliability and validity. <i>Schizophrenia Research</i> , 2003, 63, 161-170.	1.1	94
144	Cognitive performance in schizophrenia patients assessed before and following the first psychotic episode. <i>Schizophrenia Research</i> , 2003, 65, 87-94.	1.1	156
145	Transcranial Magnetic Stimulation of Left Temporoparietal Cortex and Medication-Resistant Auditory Hallucinations. <i>Archives of General Psychiatry</i> , 2003, 60, 49.	13.8	462
146	The effects of focus of attention on attributional bias in patients experiencing auditory hallucinations. <i>Behaviour Research and Therapy</i> , 2003, 41, 895-907.	1.6	44

#	ARTICLE	IF	CITATIONS
147	Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trial. <i>Biological Psychiatry</i> , 2003, 54, 444-452.	0.7	95
148	Association study between glutathione S-transferase P1 polymorphism and schizophrenia in the Korean population. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2003, 27, 519-523.	2.5	22
149	Clinician ratings vs. global ratings of symptom severity: a comparison of symptom measures in the bipolar disorder module, phase II, Texas Medication Algorithm Project. <i>Psychiatry Research</i> , 2003, 117, 167-175.	1.7	6
150	Determinants of expressed emotion in mothers of schizophrenia patients. <i>Psychiatry Research</i> , 2003, 117, 211-222.	1.7	32
151	Effects of Olanzapine on Lipid Abnormalities in Elderly Psychotic Patients. <i>Drugs and Aging</i> , 2003, 20, 893-896.	1.3	13
152	Polymorphism of the Serotonin Transporter Gene and Symptomatic Dimensions of Schizophrenia in the Korean Population. <i>Neuropsychobiology</i> , 2003, 47, 182-186.	0.9	17
153	Pharmacotherapy of first-episode psychosis. <i>Expert Opinion on Pharmacotherapy</i> , 2003, 4, 717-750.	0.9	43
154	Changes in Glucose and Cholesterol Levels in Patients With Schizophrenia Treated With Typical or Atypical Antipsychotics. <i>American Journal of Psychiatry</i> , 2003, 160, 290-296.	4.0	450
155	Efficacy of Low-Dose Mirtazapine in Neuroleptic-Induced Akathisia: A Double-Blind Randomized Placebo-Controlled Pilot Study. <i>Journal of Clinical Psychopharmacology</i> , 2003, 23, 305-308.	0.7	38
156	Substance Abuse in a Sample of Egyptian Schizophrenic Patients. <i>Addictive Disorders and Their Treatment</i> , 2003, 2, 147-150.	0.5	5
157	Decreased Plasma Antioxidants in Schizophrenia. <i>Neuropsychobiology</i> , 2004, 50, 54-56.	0.9	39
158	Neuronal Dysfunction of the Frontal Lobe in Schizophrenia. <i>Neuropsychobiology</i> , 2004, 50, 211-215.	0.9	20
159	Clozapine, Olanzapine, Risperidone, and Haloperidol in the Treatment of Patients With Chronic Schizophrenia and Schizoaffective Disorder. <i>Focus (American Psychiatric Publishing)</i> , 2004, 2, 59-67.	0.4	5
160	Phenomenological features of auditory hallucinations and their symptomatological relevance. <i>Psychiatry and Clinical Neurosciences</i> , 2004, 58, 651-659.	1.0	17
161	Delivering cognitive therapy to people with psychosis in a community mental health setting: an effectiveness study. <i>Acta Psychiatrica Scandinavica</i> , 2004, 110, 36-44.	2.2	56
162	Applying linear mixed models to estimate reliability in clinical trial data with repeated measurements. <i>Contemporary Clinical Trials</i> , 2004, 25, 13-30.	2.0	57
163	Prevalence of substance misuse among individuals with severe mental illness in São Paulo. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2004, 39, 212-217.	1.6	20
164	COMT158 polymorphism and hostility. <i>American Journal of Medical Genetics Part A</i> , 2004, 127B, 28-29.	2.4	28

#	ARTICLE	IF	CITATIONS
165	Choice of units of analysis and modeling strategies in multilevel hierarchical models. <i>Computational Statistics and Data Analysis</i> , 2004, 47, 537-563.	0.7	25
166	Cognitive therapy for the prevention of psychosis in people at ultra-high risk. <i>British Journal of Psychiatry</i> , 2004, 185, 291-297.	1.7	623
167	Drug and alcohol use among patients with schizophrenia and related psychoses: levels and consequences. <i>Schizophrenia Research</i> , 2004, 67, 157-166.	1.1	235
168	An excitement subscale of the Positive and Negative Syndrome Scale. <i>Schizophrenia Research</i> , 2004, 68, 331-337.	1.1	100
169	The Penn Conditional Exclusion Test (PCET): relationship to the Wisconsin Card Sorting Test and work function in patients with schizophrenia. <i>Schizophrenia Research</i> , 2004, 68, 95-102.	1.1	31
170	Assessment of executive dysfunction during activities of daily living in schizophrenia. <i>Schizophrenia Research</i> , 2004, 69, 289-300.	1.1	136
171	Measuring cognitive insight in middle-aged and older patients with psychotic disorders. <i>Schizophrenia Research</i> , 2004, 71, 297-305.	1.1	112
172	Recall and recognition confabulation in psychotic and bipolar disorders: evidence for two different types without unitary mechanisms. <i>Comprehensive Psychiatry</i> , 2004, 45, 281-288.	1.5	33
173	Ban1 polymorphism of the cytosolic phospholipase A2 gene may confer susceptibility to the development of schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2004, 28, 739-741.	2.5	33
174	Transcranial magnetic stimulation for auditory hallucinations in schizophrenia. <i>Psychiatry Research</i> , 2004, 127, 9-17.	1.7	122
175	Brief emotion training improves recognition of facial emotions in chronic schizophrenia. A pilot study. <i>Psychiatry Research</i> , 2004, 128, 147-154.	1.7	104
176	Mean Deviation of Inter-rater Scoring (MDIS): a simple tool for introducing conformity into groups of clinical investigators. <i>International Clinical Psychopharmacology</i> , 2004, 19, 209-213.	0.9	2
177	Monocyte chemoattractant protein-1 promoter -2518 polymorphism and schizophrenia in the Korean population. <i>Psychiatric Genetics</i> , 2004, 14, 65-67.	0.6	14
178	Assessing Disability in Older Patients With Schizophrenia. <i>Journal of Nervous and Mental Disease</i> , 2004, 192, 405-413.	0.5	132
179	Negative Symptoms, Trauma, and Autobiographical Memory. <i>Journal of Nervous and Mental Disease</i> , 2004, 192, 745-753.	0.5	49
180	Quinone oxidoreductase (NQO1) gene polymorphism (609C/T) may be associated with tardive dyskinesia, but not with the development of schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2004, 7, 495-500.	1.0	45
181	Switching elderly chronic psychotic patients to olanzapine. <i>International Journal of Neuropsychopharmacology</i> , 2004, 7, 165-169.	1.0	20
182	Abnormal response to metabolic stress in schizophrenia: marker of vulnerability or acquired sensitization?. <i>Psychological Medicine</i> , 2004, 34, 1103-1111.	2.7	45

#	ARTICLE	IF	CITATIONS
183	Benefits of Adjunct Modafinil in an Open-Label, Pilot Study in Patients With Schizophrenia. <i>Clinical Neuropharmacology</i> , 2004, 27, 38-43.	0.2	64
184	Procedural Learning in Schizophrenia Can Reflect the Pharmacologic Properties of the Antipsychotic Treatments. <i>Cognitive and Behavioral Neurology</i> , 2004, 17, 32-40.	0.5	30
185	Why Do People With Delusions Fail to Choose More Realistic Explanations for Their Experiences? An Empirical Investigation.. <i>Journal of Consulting and Clinical Psychology</i> , 2004, 72, 671-680.	1.6	183
186	Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders. <i>British Journal of Psychiatry</i> , 2004, 185, 18-24.	1.7	143
187	Anxiety and Schizophrenia: The Interaction of Subtypes of Anxiety and Psychotic Symptoms. <i>CNS Spectrums</i> , 2005, 10, 721-731.	0.7	110
188	Treatment Response to Olanzapine and Haloperidol and its Association with Dopamine D ₂ Receptor Occupancy in First-Episode Psychosis. <i>Canadian Journal of Psychiatry</i> , 2005, 50, 462-469.	0.9	24
189	A double-blind, cross-over comparison of the effects of amantadine or placebo on visuomotor and cognitive function in medicated schizophrenia patients. <i>International Clinical Psychopharmacology</i> , 2005, 20, 319-326.	0.9	23
190	Stability in schizophrenia symptoms over time: Findings from the Mount Sinai Pilgrim Psychiatric Center Longitudinal Study.. <i>Journal of Abnormal Psychology</i> , 2005, 114, 363-372.	2.0	40
191	Assessing cognitive representations of mental health problems. I. The illness perception questionnaire for schizophrenia. <i>British Journal of Clinical Psychology</i> , 2005, 44, 147-162.	1.7	83
192	Eleven-year clinical outcome of schizophrenia in Bali. <i>Acta Psychiatrica Scandinavica</i> , 2005, 112, 456-462.	2.2	24
193	Applying Concepts of Generalizability Theory on Clinical Trial Data to Investigate Sources of Variation and Their Impact on Reliability. <i>Biometrics</i> , 2005, 61, 295-304.	0.8	85
194	Visual Feedback Therapy to Enhance Medication Adherence in Psychosis. <i>Archives of Psychiatric Nursing</i> , 2005, 19, 70-80.	0.7	15
196	Quality of life and temperament factors in schizophrenia: Comparative study of patients, their siblings and controls. <i>Quality of Life Research</i> , 2005, 14, 433-440.	1.5	49
197	Development of Clinical Guidelines for the Pharmacological Management of Behavioural Disturbance and Aggression in People with Psychosis. <i>Australasian Psychiatry</i> , 2005, 13, 247-252.	0.4	21
198	A Double-Blind, Placebo-Controlled Trial of Sibutramine for Olanzapine-Associated Weight Gain. <i>American Journal of Psychiatry</i> , 2005, 162, 954-962.	4.0	136
199	A Randomized Trial of Short-Term Acute Residential Treatment for Veterans. <i>Psychiatric Services</i> , 2005, 56, 1379-1386.	1.1	20
200	ADHERENCE AND NONADHERENCE TO ANTIPSYCHOTIC MEDICATIONS. <i>Issues in Mental Health Nursing</i> , 2005, 26, 379-396.	0.6	14
201	EFFECTS OF EXERCISE ON MENTAL AND PHYSICAL HEALTH PARAMETERS OF PERSONS WITH SCHIZOPHRENIA. <i>Issues in Mental Health Nursing</i> , 2005, 26, 661-676.	0.6	221

#	ARTICLE	IF	CITATIONS
202	Telemonitoring of Medication Adherence in Patients with Schizophrenia. <i>Telemedicine Journal and E-Health</i> , 2005, 11, 675-683.	1.6	55
203	A double blind study showing that two weeks of daily repetitive TMS over the left or right temporoparietal cortex reduces symptoms in patients with schizophrenia who are having treatment-refractory auditory hallucinations. <i>Neuroscience Letters</i> , 2005, 376, 177-181.	1.0	148
204	Polymorphisms of heat shock protein 70 gene (HSPA1A, HSPA1B and HSPA1L) and schizophrenia. <i>Neuroscience Research</i> , 2005, 53, 8-13.	1.0	34
205	Temporoparietal Transcranial Magnetic Stimulation for Auditory Hallucinations: Safety, Efficacy and Moderators in a Fifty Patient Sample. <i>Biological Psychiatry</i> , 2005, 58, 97-104.	0.7	244
206	A forced five-dimensional factor analysis and concurrent validity of the Positive and Negative Syndrome Scale in Mexican schizophrenic patients. <i>Schizophrenia Research</i> , 2005, 72, 123-129.	1.1	69
207	Obsessive compulsive symptoms in schizophrenia: Frequency and clinical features. <i>Schizophrenia Research</i> , 2005, 76, 309-316.	1.1	115
208	Serum lipid profiles and schizophrenia: Effects of conventional or atypical antipsychotic drugs in Taiwan. <i>Schizophrenia Research</i> , 2005, 80, 55-59.	1.1	74
209	The European First Episode Schizophrenia Trial (EUFEST): Rationale and design of the trial. <i>Schizophrenia Research</i> , 2005, 78, 147-156.	1.1	89
210	Olfactory deficits, cognition and negative symptoms in early onset psychosis. <i>Schizophrenia Research</i> , 2005, 80, 283-293.	1.1	88
211	A 12-month prospective follow-up study of patients with schizophrenia-spectrum disorders and substance abuse: Changes in psychiatric symptoms and substance use. <i>Schizophrenia Research</i> , 2006, 83, 65-75.	1.1	53
212	Evidence that brain tissue volumes are associated with HVA reactivity to metabolic stress in schizophrenia. <i>Schizophrenia Research</i> , 2006, 86, 45-53.	1.1	22
213	Metacognitions in patients with hallucinations and obsessive-compulsive disorder: The superstition factor. <i>Behaviour Research and Therapy</i> , 2006, 44, 1091-1104.	1.6	46
214	Antipsychotic treatment may alter T-helper (TH) 2 arm cytokines. <i>International Immunopharmacology</i> , 2006, 6, 666-671.	1.7	60
215	Quality of life for patients with schizophrenia in a Japanese psychiatric hospital. <i>Psychiatry Research</i> , 2006, 144, 49-56.	1.7	20
216	A Group Intervention to Promote Healthy Self-Concepts and Guide Recovery in First Episode Schizophrenia: A Pilot Study.. <i>Psychiatric Rehabilitation Journal</i> , 2006, 30, 105-111.	0.8	42
217	Is Symptomatic Improvement in Clinical Trials of Cognitive-Behavioral Therapy for Psychosis Clinically Significant?. <i>Journal of Psychiatric Practice</i> , 2006, 12, 11-23.	0.3	27
218	Fluvoxamine as an Adjunctive Agent in Schizophrenia. <i>CNS Neuroscience & Therapeutics</i> , 2001, 7, 283-304.	4.0	41
220	Generalized reliability estimation using repeated measurements. <i>British Journal of Mathematical and Statistical Psychology</i> , 2006, 59, 113-131.	1.0	20

#	ARTICLE	IF	CITATIONS
221	Clinical characteristics and objective living conditions in relation to quality of life among community-based individuals of schizophrenia in Hong Kong. <i>Quality of Life Research</i> , 2006, 15, 1459-1469.	1.5	16
222	Interaction analysis between 5-HTTLPR and TNFA $\hat{\sim}$ 238/ $\hat{\sim}$ 308 polymorphisms in schizophrenia. <i>Journal of Neural Transmission</i> , 2006, 113, 887-897.	1.4	14
223	Training patients with schizophrenia with the community re-entry module. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2006, 41, 464-469.	1.6	31
224	Pharmacology of autism. <i>Clinical Neuroscience Research</i> , 2006, 6, 179-188.	0.8	21
225	Remission and cognitive ability in a cohort of patients with schizophrenia. <i>Journal of Psychiatric Research</i> , 2006, 40, 738-745.	1.5	81
226	Clozapine Alone versus Clozapine and Risperidone with Refractory Schizophrenia. <i>New England Journal of Medicine</i> , 2006, 354, 472-482.	13.9	249
227	Transition to Psychosis: 6-Month follow-up of a Chinese High-Risk Group in Hong Kong. <i>Australian and New Zealand Journal of Psychiatry</i> , 2006, 40, 414-420.	1.3	29
228	The Structure of Negative Symptoms Within Schizophrenia: Implications for Assessment. <i>Schizophrenia Bulletin</i> , 2006, 32, 238-245.	2.3	532
229	New Paradigms for Treatment Development. <i>Schizophrenia Bulletin</i> , 2007, 33, 1093-1099.	2.3	18
230	Efficacy of the Community Re-Entry Module for patients with schizophrenia in Beijing, China: outcome at 2-year follow-up. <i>British Journal of Psychiatry</i> , 2007, 190, 49-56.	1.7	53
231	The alignment of workforce development with service user moves towards integral self-intervention in the management of emotional states that may lead to behavioural disturbance: one Australian perspective. <i>Journal of Mental Health Training, Education and Practice</i> , 2007, 2, 13-21.	0.3	1
233	Symptom rating scales and outcome in schizophrenia. <i>British Journal of Psychiatry</i> , 2007, 191, s7-s14.	1.7	114
234	A Study of Polypharmacy with Second Generation Antipsychotics in Patients with Severe and Persistent Mental Illness. <i>Journal of Psychiatric Practice</i> , 2007, 13, 129-137.	0.3	24
235	A randomised controlled trial of a group intervention to reduce engulfment and self-stigmatisation in first episode schizophrenia. <i>Australian E-Journal for the Advancement of Mental Health</i> , 2007, 6, 212-220.	0.2	28
236	The recovery of metacognitive capacity in schizophrenia across 32 months of individual psychotherapy: A case study. <i>Psychotherapy Research</i> , 2007, 17, 713-720.	1.1	121
237	Manganese superoxide dismutase (MnSOD: Ala $\hat{\sim}$ 9Val) gene polymorphism may not be associated with schizophrenia and tardive dyskinesia. <i>Psychiatry Research</i> , 2007, 153, 77-81.	1.7	33
238	Schizophrenic patients with polydipsia and water intoxication more often have a form of schizophrenia first described by Kraepelin. <i>Psychiatry Research</i> , 2007, 152, 267-271.	1.7	25
239	Relationships between worry, psychotic experiences and emotional distress in patients with schizophrenia spectrum diagnoses and comparisons with anxious and non-patient groups. <i>Behaviour Research and Therapy</i> , 2007, 45, 1593-1600.	1.6	73

#	ARTICLE	IF	CITATIONS
240	Association of DAOA polymorphisms with schizophrenia and clinical symptoms or therapeutic effects. <i>Neuroscience Letters</i> , 2007, 416, 96-100.	1.0	36
241	A 6-month prospective, observational, naturalistic, uncontrolled study to evaluate the effectiveness and tolerability of oral ziprasidone in patients with schizophrenia. <i>European Neuropsychopharmacology</i> , 2007, 17, 456-463.	0.3	12
242	Estimating Reliability and Generalizability from Hierarchical Biomedical Data. <i>Journal of Biopharmaceutical Statistics</i> , 2007, 17, 595-627.	0.4	19
244	Remission in prognosis of functional outcome: A new dimension in the treatment of patients with psychotic disorders. <i>Schizophrenia Research</i> , 2007, 93, 160-168.	1.1	98
245	A prospective study of Quality of life in schizophrenia in three European countries. <i>Schizophrenia Research</i> , 2007, 93, 194-202.	1.1	61
246	Sexual functioning, psychopathology and quality of life in patients with schizophrenia. <i>Schizophrenia Research</i> , 2007, 94, 119-127.	1.1	60
247	Tobacco smoking in Egyptian schizophrenia patients with and without obsessive-compulsive symptoms. <i>Schizophrenia Research</i> , 2007, 95, 236-246.	1.1	23
248	Lack of support for the inability to taste phenylthiocarbamide as an endophenotypic marker in patients with schizophrenia and their first-degree relatives. <i>Schizophrenia Research</i> , 2007, 95, 65-69.	1.1	7
249	Schizophrenia: Measurements of Psychopathology. <i>Psychiatric Clinics of North America</i> , 2007, 30, 339-363.	0.7	24
250	Prevalence of tobacco use in individuals with severe mental illnesses, São Paulo, Brazil. <i>Revista De Saude Publica</i> , 2007, 41, 510-516.	0.7	6
251	Flexible surrogate marker evaluation from several randomized clinical trials with continuous endpoints, using R and SAS. <i>Computational Statistics and Data Analysis</i> , 2007, 51, 4152-4163.	0.7	10
252	Item response analysis of the Positive and Negative Syndrome Scale. <i>BMC Psychiatry</i> , 2007, 7, 66.	1.1	79
253	Path models of Quality of Life among People with Schizophrenia Living in the Community in Hong Kong. <i>Community Mental Health Journal</i> , 2008, 44, 97-112.	1.1	10
254	Subjectivity in the Perception and Measurement of Quality of Life: Conceptualization and Development of the Seville Questionnaire. <i>Psychiatric Quarterly</i> , 2008, 79, 321-330.	1.1	4
255	The needs of carers: a comparison between eating disorders and schizophrenia. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2008, 43, 800-807.	1.6	56
256	Gender aspects of parents' needs of schizophrenia patients. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2008, 43, 968-974.	1.6	29
257	The meta-analytic framework for the evaluation of surrogate endpoints in clinical trials. <i>Journal of Statistical Planning and Inference</i> , 2008, 138, 432-449.	0.4	17
258	The impact of mode of onset of psychosis on pathways to care in a hospitalized, predominantly African-American, first-episode sample. <i>Microbial Biotechnology</i> , 2008, 2, 73-79.	0.9	19

#	ARTICLE	IF	CITATIONS
259	Prolactin, Subjective Well-Being and Sexual Dysfunction: An Open Label Observational Study Comparing Quetiapine with Risperidone. <i>Journal of Sexual Medicine</i> , 2008, 5, 2816-2826.	0.3	33
260	Assessment of physical activity in middle-aged and older adults with schizophrenia. <i>Schizophrenia Research</i> , 2008, 104, 294-301.	1.1	129
261	A dysbindin risk haplotype associated with less severe manic-type symptoms in psychosis. <i>Neuroscience Letters</i> , 2008, 431, 146-149.	1.0	30
262	Predictive validity of the Family Attitude Scale in people with psychosis. <i>Psychiatry Research</i> , 2008, 160, 356-363.	1.7	18
263	Posttraumatic stress disorder, cognitive function and quality of life in patients with schizophrenia. <i>Psychiatry Research</i> , 2008, 159, 140-146.	1.7	49
264	Addition of memantine to antipsychotic treatment in schizophrenia inpatients with residual symptoms: A preliminary study. <i>European Neuropsychopharmacology</i> , 2008, 18, 117-121.	0.3	53
265	Experience of quality of life and attitude to care and treatment in patients with schizophrenia: Role of cross-sectional remission. <i>International Journal of Psychiatry in Clinical Practice</i> , 2008, 12, 97-104.	1.2	13
266	Negative symptoms in schizophrenia—A review. <i>Nordic Journal of Psychiatry</i> , 2008, 62, 334-341.	0.7	125
267	Factors that impede the discharge of long-term schizophrenic inpatients. <i>Scandinavian Journal of Occupational Therapy</i> , 2008, 15, 230-235.	1.1	0
268	Atypical Antipsychotics: CATIE Study, Drug-Induced Movement Disorder and Resulting Iatrogenic Psychiatric-Like Symptoms, Supersensitivity Rebound Psychosis and Withdrawal Discontinuation Syndromes. <i>Psychotherapy and Psychosomatics</i> , 2008, 77, 69-77.	4.0	150
269	Alternative methods to evaluate trial level surrogacy. <i>Clinical Trials</i> , 2008, 5, 194-208.	0.7	9
270	Cognitive Performance and Grey Matter Density in Psychosis: Functional Relevance of a Structural Endophenotype. <i>Neuropsychobiology</i> , 2008, 58, 128-137.	0.9	12
271	An open multicentre pilot study examining the safety, efficacy and tolerability of fast titrated (800) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 <i>Journal of Psychiatry in Clinical Practice</i> , 2008, 12, 261-267.	1.2	3
272	A Placebo-Controlled Add-On Trial of the Ampakine, CX516, for Cognitive Deficits in Schizophrenia. <i>Neuropsychopharmacology</i> , 2008, 33, 465-472.	2.8	170
273	Psychometric Properties of the Burden Inventory for Relatives of Persons with Psychotic Disturbances. <i>Psychological Reports</i> , 2008, 103, 323-335.	0.9	12
274	Generalizability in NonGaussian Longitudinal Clinical Trial Data Based on Generalized Linear Mixed Models. <i>Journal of Biopharmaceutical Statistics</i> , 2008, 18, 691-712.	0.4	3
275	The Beck Cognitive Insight Scale in Outpatients with Psychotic Disorders: Further Evidence from a French-Speaking Sample. <i>Canadian Journal of Psychiatry</i> , 2008, 53, 783-787.	0.9	66
276	Fluctuations in self-esteem and paranoia in the context of daily life.. <i>Journal of Abnormal Psychology</i> , 2008, 117, 143-153.	2.0	199

#	ARTICLE	IF	CITATIONS
277	Dynamic Assessment of Executive Functioning: (How) Can We Measure Change?. Journal of Cognitive Education and Psychology, 2008, 7, 368-387.	0.2	16
278	Evaluation of the Use of the Positive and Negative Syndrome Scale-Excited Component as a Criterion for Administration of P.R.N. Medication. Journal of Psychiatric Practice, 2008, 14, 105-113.	0.3	13
279	A Longitudinal Study of Learning Potential and Rehabilitation Outcome in Schizophrenia. Psychiatric Services, 2008, 59, 248-255.	1.1	41
280	Relationship Between Self-Focused Attention and Dissociation in Patients With and Without Auditory Hallucinations. Journal of Nervous and Mental Disease, 2008, 196, 190-197.	0.5	55
281	Experience of Subjective Symptoms in Euthymic Patients with Bipolar Disorder. Journal of Korean Medical Science, 2008, 23, 18.	1.1	9
282	Patterns of neurocognitive impairment in first-episode bipolar disorder and schizophrenia. British Journal of Psychiatry, 2009, 195, 67-72.	1.7	76
283	Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making. Expert Opinion on Pharmacotherapy, 2009, 10, 1917-1928.	0.9	69
284	Association of Cerebral Deficits With Clinical Symptoms in Antipsychotic-Naive First-Episode Schizophrenia: An Optimized Voxel-Based Morphometry and Resting State Functional Connectivity Study. American Journal of Psychiatry, 2009, 166, 196-205.	4.0	238
285	Attitude towards adherence in patients with schizophrenia at discharge. Journal of Psychiatric Research, 2009, 43, 1294-1301.	1.5	28
286	Ziprasidone as an adjuvant for clozapine or olanzapine-associated medical morbidity in chronic schizophrenia. Human Psychopharmacology, 2009, 24, 225-232.	0.7	19
287	Vocational rehabilitation for subjects with severe mental illnesses in Germany. Social Psychiatry and Psychiatric Epidemiology, 2009, 44, 523-531.	1.6	19
288	Applied psychometrics in clinical psychiatry: the pharmacopsychometric triangle. Acta Psychiatrica Scandinavica, 2009, 120, 400-409.	2.2	37
289	Schizophrenia and the Motivation for Smoking. Perspectives in Psychiatric Care, 2002, 38, 41-49.	0.9	94
290	Asenapine versus olanzapine in acute mania: a double-blind extension study. Bipolar Disorders, 2009, 11, 815-826.	1.1	105
291	Application of the Comprehensive Assessment of At-Risk Mental States (CAARMS) to the Japanese population: reliability and validity of the Japanese version of the CAARMS. Microbial Biotechnology, 2009, 3, 123-130.	0.9	34
292	The Effects of Task Engagement and Interpersonal Rapport on WCST Performance in Schizophrenia. American Journal of Psychiatric Rehabilitation, 2009, 12, 57-72.	0.7	3
293	Evaluating the reliability of multiple assessments of PTSD symptomatology: Multiple examiners, one patient. Psychiatry Research, 2009, 166, 269-280.	1.7	16
294	Objectively measured motor activity in schizophrenia challenges the validity of expert ratings. Psychiatry Research, 2009, 169, 187-190.	1.7	74

#	ARTICLE	IF	CITATIONS
295	Physical and mental health-related quality of life among older people with schizophrenia. Schizophrenia Research, 2009, 108, 207-213.	1.1	63
296	Does the presenilin 2 gene predispose to schizophrenia?. Schizophrenia Research, 2009, 109, 121-129.	1.1	15
297	Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: The MOZART study. Schizophrenia Research, 2009, 110, 80-89.	1.1	38
298	Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: The MOZART study. Schizophrenia Research, 2009, 113, 112-121.	1.1	34
299	Defining and predicting functional outcome in schizophrenia and schizophrenia spectrum disorders. Schizophrenia Research, 2009, 113, 210-217.	1.1	97
300	The importance of cross-sectional remission in schizophrenia for long-term outcome: A clinical prospective study. Schizophrenia Research, 2009, 115, 67-73.	1.1	27
301	Olanzapine orally disintegrating tablets (Zyprexa Zydis ^R) rapidly improve excitement components in the acute phase of first-episode schizophrenic patients: An open-label prospective study. World Journal of Biological Psychiatry, 2009, 10, 741-745.	1.3	10
302	Epistasis between a set of variations located in the TAAR6 and HSP-70 genes toward schizophrenia and response to antipsychotic treatment. European Neuropsychopharmacology, 2009, 19, 806-811.	0.3	11
303	Aripiprazole for Patients with Schizophrenia and Schizoaffective Disorder: An Open-Label, Randomized, Study Versus Haloperidol. CNS Spectrums, 2009, 14, 93-102.	0.7	14
304	Postpsychotic Posttraumatic Stress Disorder. Journal of Nervous and Mental Disease, 2009, 197, 841-849.	0.5	40
305	Does Clinical Judgment of Baseline Severity and Changes in Psychopathology Depend on the Patient Population?. Journal of Clinical Psychopharmacology, 2010, 30, 726-731.	0.7	24
306	Basic Emotion Recognition and Psychopathology in Schizophrenia. Journal of Nervous and Mental Disease, 2010, 198, 79-81.	0.5	40
307	An early improvement threshold to predict response and remission in first-episode schizophrenia. British Journal of Psychiatry, 2010, 196, 460-466.	1.7	42
310	Intolerance of uncertainty and distress associated with the experience of psychosis. Psychology and Psychotherapy: Theory, Research and Practice, 2010, 83, 317-324.	1.3	23
311	Duration of untreated psychosis is associated with more negative schizophrenia symptoms after acute treatment for first-episode psychosis. Clinical Psychologist, 2010, 14, 10-13.	0.5	4
312	Illness-related components for the family burden of relatives to patients with psychotic illness. Social Psychiatry and Psychiatric Epidemiology, 2010, 45, 275-283.	1.6	49
313	Neurocognition and its influencing factors in the treatment of schizophrenia—effects of aripiprazole, olanzapine, quetiapine and risperidone. Human Psychopharmacology, 2010, 25, 116-125.	0.7	47
314	Using earlier measures in a longitudinal sequence as a potential surrogate for a later one. Computational Statistics and Data Analysis, 2010, 54, 1342-1354.	0.7	8

#	ARTICLE	IF	CITATIONS
315	Cognitive behavioural therapy versus supportive therapy for persistent positive symptoms in psychotic disorders: The POSITIVE Study, a multicenter, prospective, single-blind, randomised controlled clinical trial. <i>Trials</i> , 2010, 11, 123.	0.7	26
316	Trial design issues and treatment effect modeling in multi-regional schizophrenia trials. <i>Pharmaceutical Statistics</i> , 2010, 9, 217-229.	0.7	42
317	Outcome of suicidal patients with schizophrenia: results from a naturalistic study. <i>Acta Psychiatrica Scandinavica</i> , 2010, 121, 359-370.	2.2	17
318	Relaciones entre sAntomas positivos y sensibilidad a la ansiedad en la psicosis. <i>Revista De Psicopatología Y Psicología Clínica</i> , 2010, 15, .	0.1	1
319	A unified framework for the evaluation of surrogate endpoints in mental-health clinical trials. <i>Statistical Methods in Medical Research</i> , 2010, 19, 205-236.	0.7	18
320	Quality of life and subjective well-being in schizophrenia and schizophrenia spectrum disorders: Valid predictors of symptomatic response and remission?. <i>World Journal of Biological Psychiatry</i> , 2010, 11, 729-738.	1.3	27
321	Marginal Correlation in Longitudinal Binary Data Based on Generalized Linear Mixed Models. <i>Communications in Statistics - Theory and Methods</i> , 2010, 39, 3540-3557.	0.6	7
322	A Critical Analysis and Discussion of the Appropriateness of the Schizophrenia Consensus Remission Criteria in Clinical Pharmaceutical Trials. <i>Pharmacopsychiatry</i> , 2010, 43, 245-251.	1.7	8
323	A healthy lifestyle intervention for middle-aged and older schizophrenia patients with diabetes mellitus: A 6-month follow-up analysis. <i>Schizophrenia Research</i> , 2010, 121, 203-206.	1.1	44
324	Psychometric evaluation of the Medication Satisfaction Questionnaire (MSQ) to assess satisfaction with antipsychotic medication among schizophrenia patients. <i>Schizophrenia Research</i> , 2010, 118, 271-278.	1.1	62
325	Spatial localization deficits and auditory cortical dysfunction in schizophrenia. <i>Schizophrenia Research</i> , 2010, 124, 161-168.	1.1	30
326	Relation of Positive and Negative Symptoms of Schizophrenia to Financial Capacity. <i>Psychiatry, Psychology and Law</i> , 2010, 17, 574-581.	0.9	0
327	A Preliminary Exploration of Trauma, Dissociation, and Positive Psychotic Symptoms in a Spanish Sample. <i>Journal of Trauma and Dissociation</i> , 2010, 11, 284-292.	1.0	41
329	Evaluation of the therapeutic effect of theta burst stimulation on drug-resistant auditory hallucinations in a schizophrenic patient and its impact on cognitive function and neuronal excitability: A case study. <i>Clinical Neurophysiology</i> , 2010, 121, 802.	0.7	26
330	Deficient inhibition of return in chronic but not first-episode patients with schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010, 34, 961-967.	2.5	7
331	Serum thiobarbituric acid-reactive substances and free thiol levels in schizophrenia patients: Effects of antipsychotic drugs. <i>Psychiatry Research</i> , 2010, 177, 18-21.	1.7	25
332	Deficit of inhibition motor control in untreated patients with schizophrenia: Further support from visually guided saccade paradigms. <i>Psychiatry Research</i> , 2010, 179, 279-284.	1.7	16
333	A framework for understanding experiential deficits in schizophrenia. <i>Psychiatry Research</i> , 2010, 178, 10-16.	1.7	20

#	ARTICLE	IF	CITATIONS
334	Localization of cerebral functional deficits in treatment-naive, first-episode schizophrenia using resting-state fMRI. <i>NeuroImage</i> , 2010, 49, 2901-2906.	2.1	140
335	Handbook of Clinical Rating Scales and Assessment in Psychiatry and Mental Health. , 2010, , .		58
336	Pharmacogenetics of Response to Antipsychotics in Patients with Schizophrenia. <i>CNS Drugs</i> , 2011, 25, 933-969.	2.7	90
337	A pilot investigation of the Graduated Recovery Intervention Program (GRIP) for first episode psychosis. <i>Schizophrenia Research</i> , 2011, 125, 247-256.	1.1	33
338	Duration of untreated illness in schizophrenia is not associated with 5-year brain volume change. <i>Schizophrenia Research</i> , 2011, 132, 84-90.	1.1	29
339	ZNF804A risk allele is associated with relatively intact gray matter volume in patients with schizophrenia. <i>NeuroImage</i> , 2011, 54, 2132-2137.	2.1	78
340	Trauma and comorbid posttraumatic stress disorder in individuals with schizophrenia and substance abuse. <i>Comprehensive Psychiatry</i> , 2011, 52, 490-497.	1.5	21
341	The metacognitive beliefs account of hallucinatory experiences: A literature review and meta-analysis. <i>Clinical Psychology Review</i> , 2011, 31, 850-864.	6.0	64
342	A feasibility study of Acceptance and Commitment Therapy for emotional dysfunction following psychosis. <i>Behaviour Research and Therapy</i> , 2011, 49, 901-907.	1.6	132
343	Are the available apathy measures reliable and valid? A review of the psychometric evidence. <i>Journal of Psychosomatic Research</i> , 2011, 70, 73-97.	1.2	175
344	Declarative memory and WCST-64 performance in subjects with schizophrenia and healthy controls. <i>Psychiatry Research</i> , 2011, 188, 191-196.	1.7	10
345	Carbon dioxide induction of panic anxiety in schizophrenia with auditory hallucinations. <i>Psychiatry Research</i> , 2011, 189, 38-42.	1.7	13
346	Response and remission of subjective well-being in patients suffering from schizophrenia spectrum disorders. <i>European Psychiatry</i> , 2011, 26, 284-292.	0.1	11
347	Predictors of response and remission in the acute treatment of first-episode schizophrenia patients – Is it all about early response?. <i>European Neuropsychopharmacology</i> , 2011, 21, 370-378.	0.3	46
348	In vivo type II T-helper cells shift in schizophrenia compared to sex- and age-matched healthy controls. <i>European Journal of Psychiatry</i> , 2011, 25, 192-204.	0.7	4
349	Autonomic Modulation and Health-Related Quality of Life among Schizophrenic Patients Treated with Non-Intensive Case Management. <i>PLoS ONE</i> , 2011, 6, e26378.	1.1	19
350	Improving insight into delusions: a pilot study of metacognitive training for patients with schizophrenia. <i>Journal of Advanced Nursing</i> , 2011, 67, 401-407.	1.5	48
351	Clinical differences between immigrants voluntarily and involuntarily admitted to acute psychiatric units: a 3-year prospective study. <i>Journal of Psychiatric and Mental Health Nursing</i> , 2011, 18, 671-676.	1.2	10

#	ARTICLE	IF	CITATIONS
352	Evaluating depressive symptoms and their impact on outcome in schizophrenia applying the Calgary Depression Scale. <i>Acta Psychiatrica Scandinavica</i> , 2011, 123, 228-238.	2.2	45
353	Differential results between self-report and interview-based ratings of risk symptoms of psychosis. <i>Microbial Biotechnology</i> , 2011, 5, 309-314.	0.9	20
354	Influencing factors and predictors of early improvement in the acute treatment of schizophrenia and schizophrenia spectrum disorder. <i>Journal of Psychiatric Research</i> , 2011, 45, 1639-1647.	1.5	22
355	Emotions, self-esteem, and paranoid episodes: An experience sampling study. <i>British Journal of Clinical Psychology</i> , 2011, 50, 178-195.	1.7	188
356	Co-morbid PTSD and suicidality in individuals with schizophrenia and substance and alcohol abuse. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2011, 46, 1079-1086.	1.6	25
357	Use of NON-PARAMETRIC Item Response Theory to develop a shortened version of the Positive and Negative Syndrome Scale (PANSS). <i>BMC Psychiatry</i> , 2011, 11, 178.	1.1	38
358	Estimating transformations for repeated measures modeling of continuous bounded outcome data. <i>Statistics in Medicine</i> , 2011, 30, 935-949.	0.8	28
359	Cognitive Behavioural Therapy for Auditory Hallucinations: Effectiveness and Predictors of Outcome in a Specialist Clinic. <i>Behavioural and Cognitive Psychotherapy</i> , 2011, 39, 129-138.	0.9	39
360	Depersonalization as a Mediator in the Relationship Between Self-Focused Attention and Auditory Hallucinations. <i>Journal of Trauma and Dissociation</i> , 2011, 12, 535-548.	1.0	30
361	Influence of cognition and symptoms of schizophrenia on IADL performance. <i>Scandinavian Journal of Occupational Therapy</i> , 2011, 18, 180-187.	1.1	27
362	Social anxiety in schizophrenia. <i>Middle East Current Psychiatry</i> , 2011, 18, 37-44.	0.5	2
363	Positive symptoms and white matter microstructure in never-medicated first episode schizophrenia. <i>Psychological Medicine</i> , 2011, 41, 1709-1719.	2.7	84
364	Antipsychotic prophylaxis is needed after remission from a first psychotic episode in schizophrenia patients: Results from an aborted randomised trial. <i>International Journal of Psychiatry in Clinical Practice</i> , 2011, 15, 128-134.	1.2	32
365	The Application of Multiplexed Assay Systems for Molecular Diagnostics. <i>International Review of Neurobiology</i> , 2011, 101, 259-278.	0.9	0
366	The relationship between dissociation and auditory verbal hallucinations in the flow of daily life of patients with psychosis. <i>Psychosis</i> , 2011, 3, 14-28.	0.4	57
367	Atypical Antipsychotics: The Two New Arrivals. <i>Issues in Mental Health Nursing</i> , 2011, 32, 85-86.	0.6	1
368	Symptom-Specific Rating Scales in Child and Adolescent Psychiatry Clinical Practice. <i>Child and Adolescent Psychopharmacology News</i> , 2011, 16, 6-8,10.	0.1	0
369	Childhood Trauma and Hippocampal and Amygdalar Volumes in First-Episode Psychosis. <i>Schizophrenia Bulletin</i> , 2012, 38, 1162-1169.	2.3	77

#	ARTICLE	IF	CITATIONS
370	Dissociation, trauma, and the role of lived experience: Toward a new conceptualization of voice hearing.. Psychological Bulletin, 2012, 138, 28-76.	5.5	191
371	Akathisia and Suicidal Ideation in First-Episode Schizophrenia. Journal of Clinical Psychopharmacology, 2012, 32, 694-698.	0.7	29
372	Cognitive therapy for people with a schizophrenia spectrum diagnosis not taking antipsychotic medication: an exploratory trial. Psychological Medicine, 2012, 42, 1049-1056.	2.7	58
374	Evaluating Depressive Symptoms in Schizophrenia: A Psychometric Comparison of the Calgary Depression Scale for Schizophrenia and the Hamilton Depression Rating Scale. Psychopathology, 2012, 45, 276-285.	1.1	46
375	Absence of evidence for bornavirus infection in schizophrenia, bipolar disorder and major depressive disorder. Molecular Psychiatry, 2012, 17, 486-493.	4.1	82
376	Cerebral blood flow identifies responders to transcranial magnetic stimulation in auditory verbal hallucinations. Translational Psychiatry, 2012, 2, e189-e189.	2.4	62
377	Depressive symptoms and their association with acute treatment outcome in first-episode schizophrenia patients: Comparing treatment with risperidone and haloperidol. World Journal of Biological Psychiatry, 2012, 13, 30-38.	1.3	23
378	KRAEPELÄ°N Ä-LÄ±ÄœTLERÄ°NE UYAN ÅžÄ°ZOFRENÄ° HASTALARINDA KLÄ°NÄ°K, NÄ°-ROKOGNÄ°TÄ°F, YAPISAL GÄ°-RÄ°NTÄ°LEMEYİ DERMATOGLÄ°FÄ°K Ä-ZELLÄ°KLER. Noropsikiyatri Arsivi, 2012, 49, 1-1.	0.7	1
379	Dissociation mediates the relationship between childhood trauma and hallucination-proneness. Psychological Medicine, 2012, 42, 1025-1036.	2.7	213
380	Dynamics of Self-Esteem in â€œPoor-Meâ€ and â€œBad-Meâ€ Paranoia. Journal of Nervous and Mental Disease, 2012, 200, 777-783.	0.5	20
381	Effects of cognitive remediation on neurocognitive functions and psychiatric symptoms in schizophrenia inpatients. Schizophrenia Research, 2012, 142, 165-170.	1.1	24
382	Relationship of metacognition, absorption, and depersonalization in patients with auditory hallucinations. British Journal of Clinical Psychology, 2012, 51, 100-118.	1.7	42
383	Insight in schizophreniaâ€‘course and predictors during the acute treatment phase of patients suffering from a schizophrenia spectrum disorder. European Psychiatry, 2012, 27, 625-633.	0.1	31
384	One-year functional outcomes of naturalistically treated patients with schizophrenia. Psychiatry Research, 2012, 198, 378-385.	1.7	34
386	Caratteristiche cliniche, sociodemografiche e criticitÄ nella cura del paziente affetto da patologia mentale detenuto in Italia: studio osservazionale di casi consecutivi della durata di sei mesi. Quaderni Italiani Di Psichiatria, 2012, 31, 92-111.	0.1	1
387	Older Patients With Schizophrenia: Does Military Veteran Status Matter?. American Journal of Geriatric Psychiatry, 2012, 20, 248-256.	0.6	11
388	Anxiety and depression and their links with delusions and hallucinations in people with a dual diagnosis of psychosis and substance misuse: A study using data from a randomised controlled trial. Behaviour Research and Therapy, 2012, 50, 65-71.	1.6	18
389	A preliminary exploration of predictors of outcome and cognitive mechanisms of change in cognitive behaviour therapy for psychosis in people not taking antipsychotic medication. Behaviour Research and Therapy, 2012, 50, 163-167.	1.6	33

#	ARTICLE	IF	CITATIONS
390	Prevalence of depression and its relationship with other clinical characteristics in a sample of patients with stable schizophrenia. <i>Comprehensive Psychiatry</i> , 2012, 53, 145-151.	1.5	90
391	The relationship between metacognitive beliefs, auditory hallucinations, and hallucination-related distress in clinical and non-clinical voice-hearers. <i>British Journal of Clinical Psychology</i> , 2012, 51, 434-447.	1.7	39
392	Cognitive adaptation training combined with assertive community treatment: A randomised longitudinal trial. <i>Schizophrenia Research</i> , 2012, 135, 105-111.	1.1	28
393	Effect of cannabis use on the course of schizophrenia in male patients: A prospective cohort study. <i>Schizophrenia Research</i> , 2012, 137, 50-57.	1.1	63
394	Hippocampal novelty activations in schizophrenia: Disease and medication effects. <i>Schizophrenia Research</i> , 2012, 138, 157-163.	1.1	27
395	Response trajectories in "real-world" naturalistically treated schizophrenia patients. <i>Schizophrenia Research</i> , 2012, 139, 218-224.	1.1	26
396	Cholinergic pathways and cognition in patients with schizophrenia: A pilot study. <i>Schizophrenia Research</i> , 2012, 139, 46-52.	1.1	8
397	Medical writing for CNS indications. , 0, , 156-168.		0
398	Dissociative experiences as mediators between childhood trauma and auditory hallucinations. <i>Journal of Traumatic Stress</i> , 2012, 25, 323-329.	1.0	105
399	Power spectrum scale invariance identifies prefrontal dysregulation in paranoid schizophrenia. <i>Human Brain Mapping</i> , 2012, 33, 1582-1593.	1.9	21
400	Safety of quetiapine fumarate extended release in the treatment of Korean patients with acute schizophrenia. <i>Human Psychopharmacology</i> , 2012, 27, 403-410.	0.7	1
401	Quality of life and illness beliefs in individuals with early psychosis. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2012, 47, 545-551.	1.6	28
402	Remission and Recovery and their Predictors in Schizophrenia Spectrum Disorder: Results from a 1-Year Follow-Up Naturalistic Trial. <i>Psychiatric Quarterly</i> , 2012, 83, 187-207.	1.1	19
403	Association study of myelin transcription factor 1-like polymorphisms with schizophrenia in Han Chinese population. <i>Genes, Brain and Behavior</i> , 2012, 11, 87-93.	1.1	26
404	Association between Ghrelin gene (GHLR) polymorphisms and clinical response to atypical antipsychotic drugs in Han Chinese schizophrenia patients. <i>Behavioral and Brain Functions</i> , 2012, 8, 11.	1.4	25
405	Critical trial-related criteria in acute schizophrenia studies. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012, 262, 151-155.	1.8	6
406	Power and Perceived Expressed Emotion of Voices: Their Impact on Depression and Suicidal Thinking in Those Who Hear Voices. <i>Clinical Psychology and Psychotherapy</i> , 2013, 20, 199-205.	1.4	14
407	Conformance to schizophrenia treatment guidelines in North West-Bank, Palestine: focus on antipsychotic dosing and polytherapy. <i>BMC Psychiatry</i> , 2013, 13, 179.	1.1	8

#	ARTICLE	IF	CITATIONS
408	Psychosocial and neuropsychiatric predictors of subjective recovery from psychosis. <i>Psychiatry Research</i> , 2013, 208, 203-209.	1.7	46
409	Cyproheptadine for Prevention of Neuropsychiatric Adverse Effects of Efavirenz: A Randomized Clinical Trial. <i>AIDS Patient Care and STDs</i> , 2013, 27, 146-154.	1.1	13
410	The longitudinal interplay between negative and positive symptom trajectories in patients under antipsychotic treatment: a post hoc analysis of data from a randomized, 1-year pragmatic trial. <i>BMC Psychiatry</i> , 2013, 13, 320.	1.1	21
411	Clinical correlates of objective and subjective quality of life among middle-aged and elderly female inpatients with chronic schizophrenia. <i>Asian Journal of Psychiatry</i> , 2013, 6, 389-393.	0.9	5
412	Theta burst transcranial magnetic stimulation for the treatment of auditory verbal hallucinations: Results of a randomized controlled study. <i>Psychiatry Research</i> , 2013, 209, 114-117.	1.7	42
413	Virtual Environments Using Video Capture for Social Phobia with Psychosis. <i>Cyberpsychology, Behavior, and Social Networking</i> , 2013, 16, 473-479.	2.1	27
414	Neurological soft signs discriminate schizophrenia from major depression but not bipolar disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2013, 43, 72-78.	2.5	63
415	Exercise therapy improves mental and physical health in schizophrenia: a randomised controlled trial. <i>Acta Psychiatrica Scandinavica</i> , 2013, 127, 464-473.	2.2	196
416	Bcl-2 associated with positive symptoms of schizophrenic patients in an acute phase. <i>Psychiatry Research</i> , 2013, 210, 735-738.	1.7	9
417	Reduced Neuronal Activity in Language-Related Regions After Transcranial Magnetic Stimulation Therapy for Auditory Verbal Hallucinations. <i>Biological Psychiatry</i> , 2013, 73, 518-524.	0.7	93
418	Changes in oxidative stress markers in patients with schizophrenia: The effect of antipsychotic drugs. <i>Psychiatry Research</i> , 2013, 209, 284-290.	1.7	43
419	Depression and Anxiety Following Psychosis: Associations with Mindfulness and Psychological Flexibility. <i>Behavioural and Cognitive Psychotherapy</i> , 2013, 41, 34-51.	0.9	20
420	Sensitivity of individual items of the Positive and Negative Syndrome Scale (PANSS) and items subgroups to differentiate between placebo and drug treatment in schizophrenia. <i>Schizophrenia Research</i> , 2013, 146, 53-58.	1.1	6
421	Early Antipsychotic Response to Aripiprazole in Adolescents With Schizophrenia: Predictive Value for Clinical Outcomes. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2013, 52, 689-698.e3.	0.3	23
423	Self-attacking and self-reassurance in persecutory delusions: A comparison of healthy, depressed and paranoid individuals. <i>Psychiatry Research</i> , 2013, 205, 127-136.	1.7	37
424	Cognitive Performance of Individuals With Schizophrenia Across Seven Decades: A Study Using the MATRICS Consensus Cognitive Battery. <i>American Journal of Geriatric Psychiatry</i> , 2013, 21, 108-118.	0.6	68
425	Psychopathology, rehospitalization and quality of life among patients with schizophrenia under home care case management in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2013, 112, 208-215.	0.8	14
426	Exercise therapy, cardiorespiratory fitness and their effect on brain volumes: A randomised controlled trial in patients with schizophrenia and healthy controls. <i>European Neuropsychopharmacology</i> , 2013, 23, 675-685.	0.3	119

#	ARTICLE	IF	CITATIONS
427	Atypical Antipsychotics in the Treatment of Depressive and Psychotic Symptoms in Patients with Chronic Schizophrenia: A Naturalistic Study. <i>Schizophrenia Research and Treatment</i> , 2013, 2013, 1-7.	0.7	6
428	Transcranial Magnetic Stimulation of Wernicke's and Right Homologous Sites to Curtail "Voices": A Randomized Trial. <i>Biological Psychiatry</i> , 2013, 73, 1008-1014.	0.7	70
429	Association of serotonin transporter gene (SLC6A4) polymorphisms with schizophrenia susceptibility and symptoms in a Chinese-Han population. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2013, 44, 290-295.	2.5	24
430	Adjuvant therapy with minocycline for schizophrenia (The MINOS Trial): study protocol for a double-blind randomized placebo-controlled trial. <i>Trials</i> , 2013, 14, 406.	0.7	15
431	Insight, Neurocognition, and Schizophrenia: Predictive Value of the Wisconsin Card Sorting Test. <i>Schizophrenia Research and Treatment</i> , 2013, 2013, 1-6.	0.7	4
432	An Open-Label, Randomized, Controlled Trial of Zolpidem and Risperidone for Acutely Ill, Hospitalized, Schizophrenic Patients With Symptoms of Agitation. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 747-752.	0.7	6
433	Cognitive impairment and neurological soft signs in an Egyptian sample of schizophrenia patients. <i>Middle East Current Psychiatry</i> , 2013, 20, 14-21.	0.5	1
434	Anatomical and Functional Brain Abnormalities in Drug-Naive First-Episode Schizophrenia. <i>American Journal of Psychiatry</i> , 2013, 170, 1308-1316.	4.0	133
435	Prevalence of depression in schizophrenic patients evaluated by the Calgary Depression Scale in Shebin El-Kom, Menoufiya. <i>Middle East Current Psychiatry</i> , 2013, 20, 191-196.	0.5	4
436	The Effects of Acupuncture Treatment on Sleep Quality and on Emotional Measures among Individuals Living with Schizophrenia: A Pilot Study. <i>Sleep Disorders</i> , 2013, 2013, 1-11.	0.8	13
437	Should early improvement be redefined to better predict the maintenance of response in first-episode schizophrenia patients?. <i>Acta Psychiatrica Scandinavica</i> , 2013, 127, 474-481.	2.2	10
438	Disordered semantic activation in disorganized discourse in schizophrenia: a new pragmatic linguistic tool for structure and meaning reconstruction. <i>International Journal of Language and Communication Disorders</i> , 2013, 48, 320-328.	0.7	4
439	Predictive value of symptoms for quality of life in first-episode schizophrenia. <i>Nordic Journal of Psychiatry</i> , 2013, 67, 153-158.	0.7	16
440	The relationship between childhood trauma and neuropsychological functioning in first episode psychosis. <i>Psychosis</i> , 2013, 5, 48-59.	0.4	17
441	Semantics, pragmatics, and formal thought disorders in people with schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 177.	1.0	17
442	Through the looking glass: self-reassuring meta-cognitive capacity and its relationship with the thematic content of voices. <i>Frontiers in Human Neuroscience</i> , 2013, 7, 213.	1.0	18
443	Repeated measurements of cerebral blood flow in the left superior temporal gyrus reveal tonic hyperactivity in patients with auditory verbal hallucinations: a possible trait marker. <i>Frontiers in Human Neuroscience</i> , 2013, 7, 304.	1.0	37
444	Impact of Substance Use Disorder on Presentation and Short-Term Course of Schizophrenia. <i>Psychiatry Journal</i> , 2014, 2014, 1-9.	0.7	9

#	ARTICLE	IF	CITATIONS
445	The role of magical thinking in hallucinations. Comparisons of clinical and non-clinical groups. <i>Nordic Journal of Psychiatry</i> , 2014, 68, 605-610.	0.7	9
446	Rumination, Depressive Symptoms and Awareness of Illness in Schizophrenia. <i>Behavioural and Cognitive Psychotherapy</i> , 2014, 42, 143-155.	0.9	33
447	Plasma homocysteine levels in depression and schizophrenia in South Indian Tamilian population. <i>Indian Journal of Psychiatry</i> , 2014, 56, 46.	0.4	25
448	Association of MicroRNA137 Gene Polymorphisms with Age at Onset and Positive Symptoms of Schizophrenia in a Han Chinese Population. <i>International Journal of Psychiatry in Medicine</i> , 2014, 47, 153-168.	0.8	19
449	Cannabis Use and Dependence among French Schizophrenic Inpatients. <i>Frontiers in Psychiatry</i> , 2014, 5, 82.	1.3	11
450	Effects of antipsychotics on bone mineral density and prolactin levels in patients with schizophrenia: a 12-month prospective study. <i>Human Psychopharmacology</i> , 2014, 29, 183-189.	0.7	38
451	Effects of Dopamine D2/D3 Blockade on Human Sensory and Sensorimotor Gating in Initially Antipsychotic-Naive, First-Episode Schizophrenia Patients. <i>Neuropsychopharmacology</i> , 2014, 39, 3000-3008.	2.8	44
452	Prolonged cortical silent period among drug-naive subjects at ultra-high risk of psychosis. <i>Schizophrenia Research</i> , 2014, 160, 124-130.	1.1	13
453	Is it possible to combine different psychotic symptom scales in bipolar disorder?. <i>Psychiatry Research</i> , 2014, 220, 1090-1093.	1.7	3
454	Patterns and Correlates of Expressed Emotion, Perceived Criticism, and Rearing Style in First Admitted Early-Onset Schizophrenia Spectrum Disorders. <i>Journal of Nervous and Mental Disease</i> , 2014, 202, 783-787.	0.5	13
455	Effects of discontinuing anticholinergic treatment on movement disorders, cognition and psychopathology in patients with schizophrenia. <i>Therapeutic Advances in Psychopharmacology</i> , 2014, 4, 257-267.	1.2	32
456	Neural Correlates of Emotion Regulation in Patients with Schizophrenia and Non-Affected Siblings. <i>PLoS ONE</i> , 2014, 9, e99667.	1.1	69
457	Clinical profile of cannabis-induced psychosis in comparison to schizophrenia. <i>Middle East Current Psychiatry</i> , 2014, 21, 230-236.	0.5	1
458	Psychometric properties of the Questionnaire about the Process of Recovery (QPR). <i>Schizophrenia Research</i> , 2014, 156, 184-189.	1.1	107
459	Heat shock protein 70 gene polymorphisms are associated with paranoid schizophrenia in the Polish population. <i>Cell Stress and Chaperones</i> , 2014, 19, 205-215.	1.2	22
460	Perceived empowerment in people with a dual diagnosis of schizophrenia spectrum disorder and substance misuse. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2014, 49, 377-384.	1.6	12
461	Evaluation of the impact of a psycho-educational intervention on knowledge levels and psychological outcomes for people diagnosed with Schizophrenia and their caregivers in Jordan: a randomized controlled trial. <i>BMC Psychiatry</i> , 2014, 14, 17.	1.1	10
462	Neurobiological effects of physical exercise in schizophrenia: a systematic review. <i>Disability and Rehabilitation</i> , 2014, 36, 1749-1754.	0.9	63

#	ARTICLE	IF	CITATIONS
463	Relationship Between Childhood Trauma, Mindfulness, and Dissociation in Subjects With and Without Hallucination Proneness. <i>Journal of Trauma and Dissociation</i> , 2014, 15, 35-51.	1.0	48
464	Severity of psychotic episodes in predicting concurrent depressive and anxiety features in acute phase schizophrenia. <i>BMC Psychiatry</i> , 2014, 14, 166.	1.1	21
465	Symptom changes in five dimensions of the Positive and Negative Syndrome Scale in refractory psychosis. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2014, 264, 673-682.	1.8	21
466	Association of white matter deficits with clinical symptoms in antipsychotic-naïve first-episode schizophrenia: an optimized VBM study using 3T. <i>Magnetic Resonance Materials in Physics, Biology, and Medicine</i> , 2014, 27, 283-290.	1.1	14
467	Reliability, validity and ability to detect change of the PANSS negative symptom factor score in outpatients with schizophrenia on select antipsychotics and with prominent negative or disorganized thought symptoms. <i>Psychiatry Research</i> , 2014, 218, 219-224.	1.7	23
468	Depression, Diabetic Complications and Disability Among Persons With Comorbid Schizophrenia and Type 2 Diabetes. <i>Psychosomatics</i> , 2014, 55, 343-351.	2.5	4
469	Relationships Among Self, Others, and Persecutors in Individuals With Persecutory Delusions: A Repertory Grid Analysis. <i>Behavior Therapy</i> , 2014, 45, 273-282.	1.3	11
470	Voxel-based gray and white matter morphometry correlates of hallucinations in schizophrenia: The superior temporal gyrus does not stand alone. <i>NeuroImage: Clinical</i> , 2014, 4, 249-257.	1.4	62
471	Metacognitive therapy in people with a schizophrenia spectrum diagnosis and medication resistant symptoms: A feasibility study. <i>Journal of Behavior Therapy and Experimental Psychiatry</i> , 2014, 45, 280-284.	0.6	71
472	Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: a single-blind randomised controlled trial. <i>Lancet, The</i> , 2014, 383, 1395-1403.	6.3	196
473	The role of experiential avoidance in paranoid delusions: An experience sampling study. <i>British Journal of Clinical Psychology</i> , 2014, 53, 422-432.	1.7	47
474	Auditory Verbal Hallucinations: can Beliefs about Voices Mediate the Relationship Patients establish with them and Negative Affect?. <i>Spanish Journal of Psychology</i> , 2015, 18, E76.	1.1	4
475	A brief intervention to improve exercising in patients with schizophrenia: a controlled pilot study with mental contrasting and implementation intentions (MCII). <i>BMC Psychiatry</i> , 2015, 15, 211.	1.1	38
476	Trauma in relation to psychosis and hospital experiences: The role of past trauma and attachment. <i>Psychology and Psychotherapy: Theory, Research and Practice</i> , 2015, 88, 227-239.	1.3	17
477	Cognitive remediation for older community-dwelling individuals with schizophrenia: a pilot and feasibility study. <i>International Journal of Geriatric Psychiatry</i> , 2015, 30, 1129-1134.	1.3	10
478	Impairments in Negative Facial Emotion Recognition in Chinese Schizophrenia Patients Detected With a Newly Designed Task. <i>Journal of Nervous and Mental Disease</i> , 2015, 203, 718-724.	0.5	10
479	Relación entre trauma, disociación y síntomas psicóticos positivos. <i>Acción Psicológica</i> , 2015, 12, 95-108.	0.1	1
480	Predictors of quality of life among individuals with schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2015, 11, 1371.	1.0	29

#	ARTICLE	IF	CITATIONS
481	Telomere length in blood cells is related to the chronicity, severity, and recurrence rate of schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2015, 11, 1493.	1.0	18
482	Psychosocial functioning in schizophrenia: are some symptoms or demographic characteristics predictors across the functioning domains?. <i>Neuropsychiatric Disease and Treatment</i> , 2015, 11, 2471.	1.0	18
483	Plasma peptidases as prognostic biomarkers in patients with first-episode psychosis. <i>Psychiatry Research</i> , 2015, 228, 197-202.	1.7	6
484	Impact of attachment style on the 1-year outcome of persons with an at-risk mental state for psychosis. <i>Psychiatry Research</i> , 2015, 228, 849-856.	1.7	16
485	Schizophrenia-Like Symptoms in Narcolepsy Type 1: Shared and Distinctive Clinical Characteristics. <i>Neuropsychobiology</i> , 2015, 71, 218-224.	0.9	29
486	What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trial. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2015, 265, 107-116.	1.8	26
487	Mixing apples with oranges: Visual attention deficits in schizophrenia. <i>Journal of Behavior Therapy and Experimental Psychiatry</i> , 2015, 48, 27-32.	0.6	6
488	What are depressive symptoms in acutely ill patients with schizophrenia spectrum disorder?. <i>European Psychiatry</i> , 2015, 30, 43-50.	0.1	18
489	Sensory modulation and daily-life participation in people with schizophrenia. <i>Comprehensive Psychiatry</i> , 2015, 58, 130-137.	1.5	19
490	On the use of the Positive and Negative Syndrome Scale in randomized clinical trials. <i>Schizophrenia Research</i> , 2015, 165, 181-187.	1.1	20
491	Predicting the future in schizophrenia: The discrepancy between anticipatory and consummatory pleasure. <i>Psychiatry Research</i> , 2015, 229, 462-469.	1.7	18
492	Is conceptual implicit memory impaired in schizophrenia? Evidence from lexical decision and category verification. <i>Cognitive Neuropsychiatry</i> , 2015, 20, 41-52.	0.7	5
493	Changes in delusional dimensions and emotions over eight weeks of antipsychotic treatment in acute patients. <i>Psychiatry Research</i> , 2015, 228, 393-398.	1.7	4
494	Prediction of Working Memory Performance in Schizophrenia by Plasma Ratio of Clozapine to <i>N</i> -Desmethylclozapine. <i>American Journal of Psychiatry</i> , 2015, 172, 579-585.	4.0	63
495	Reliability and validity of a new scale for measuring relationships with voices: The DAIMON Scale. <i>Psychosis</i> , 2015, 7, 312-323.	0.4	6
496	Evaluation of the impact of a psycho-educational intervention for people diagnosed with schizophrenia and their primary caregivers in Jordan: a randomized controlled trial. <i>BMC Psychiatry</i> , 2015, 15, 72.	1.1	31
497	From hospital admission to independent living: Is prediction possible?. <i>Psychiatry Research</i> , 2015, 226, 499-506.	1.7	3
498	Relationship between self-focused attention, mindfulness and distress in individuals with auditory verbal hallucinations. <i>Cognitive Neuropsychiatry</i> , 2015, 20, 482-488.	0.7	12

#	ARTICLE	IF	CITATIONS
499	Does cognitive impairment in treatment-resistant and ultra-treatment-resistant schizophrenia differ from that in treatment responders?. <i>Psychiatry Research</i> , 2015, 230, 811-818.	1.7	17
500	Acceptance and Commitment Therapy for depression following psychosis: An examination of clinically significant change. <i>Journal of Contextual Behavioral Science</i> , 2015, 4, 203-209.	1.3	10
501	Evaluation of auditory hallucinations in patients with schizophrenia: A validation study of the Malay version of Psychotic Symptom Rating Scales (PSYRATS). <i>Psychiatry Research</i> , 2015, 228, 462-467.	1.7	10
502	The Effectiveness of a Patient-Centred Assessment with a Solution-Focused Approach (DIALOG+) for Patients with Psychosis: A Pragmatic Cluster-Randomised Controlled Trial in Community Care. <i>Psychotherapy and Psychosomatics</i> , 2015, 84, 304-313.	4.0	79
503	Preserved priming effect in individuals with schizophrenia: cues towards rehabilitation. <i>Cognitive Neuropsychiatry</i> , 2015, 20, 512-525.	0.7	2
504	Omega-3 fatty acids in first-episode schizophrenia - a randomized controlled study of efficacy and relapse prevention (OFFER): rationale, design, and methods. <i>BMC Psychiatry</i> , 2015, 15, 97.	1.1	41
505	Randomized controlled trial of computer-based treatment of social cognition in schizophrenia: the TRuSST trial protocol. <i>BMC Psychiatry</i> , 2015, 15, 142.	1.1	26
506	Effect of Ramadan fasting on anthropometric, metabolic, inflammatory and psychopathology status of Egyptian male patients with schizophrenia. <i>Psychiatry Research</i> , 2015, 225, 501-508.	1.7	20
507	Altered Cortical Thickness Related to Clinical Severity But Not the Untreated Disease Duration in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2015, 41, 201-210.	2.3	94
508	Static and Dynamic Characteristics of Cerebral Blood Flow During the Resting State in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2015, 41, 163-170.	2.3	83
509	The Impact of Aging, Cognition, and Symptoms on Functional Competence in Individuals With Schizophrenia Across the Lifespan. <i>Schizophrenia Bulletin</i> , 2015, 41, 374-381.	2.3	55
510	Relationship between Erythrocyte Fatty Acid Composition and Psychopathology in the Vienna Omega-3 Study. <i>PLoS ONE</i> , 2016, 11, e0151417.	1.1	22
511	Visual Hallucinations in First-Episode Psychosis: Association with Childhood Trauma. <i>PLoS ONE</i> , 2016, 11, e0153458.	1.1	22
512	“Everyone Needs a Friend Sometimes” Social Predictors of Long-Term Remission In First Episode Psychosis. <i>Frontiers in Psychology</i> , 2016, 7, 1491.	1.1	11
514	Posttraumatic Stress Disorder Symptoms and Social and Occupational Functioning of People With Schizophrenia. <i>Journal of Nervous and Mental Disease</i> , 2016, 204, 590-598.	0.5	13
515	Self-Efficacy and Hemoglobin A1C Among Adults With Serious Mental Illness and Type 2 Diabetes. <i>Psychosomatic Medicine</i> , 2016, 78, 263-270.	1.3	14
516	Effects of ignoring clustered data structure in confirmatory factor analysis of ordered polytomous items: a simulation study based on PANSS. <i>International Journal of Methods in Psychiatric Research</i> , 2016, 25, 205-219.	1.1	6
517	Challenging the understanding of significant improvement and outcome in schizophrenia – the concept of reliable and clinically significant change methods. <i>International Journal of Methods in Psychiatric Research</i> , 2016, 25, 3-11.	1.1	5

#	ARTICLE	IF	CITATIONS
518	Longitudinal predictors of subjective recovery in psychosis. <i>British Journal of Psychiatry</i> , 2016, 209, 48-53.	1.7	43
519	Parental and God Representations Among Individuals with Psychosis: A Grounded Theory Analysis. <i>Journal of Religion and Health</i> , 2016, 55, 2141-2153.	0.8	5
520	Factors discriminating employment status following in-patient evaluation among persons with schizophrenia. <i>Work</i> , 2016, 53, 469-478.	0.6	2
521	Extent and pattern of burden of care and its associated factors among Eritrean families of persons living with schizophrenia: a cross-sectional study. <i>BMJ Open</i> , 2016, 6, e012127.	0.8	8
524	A qualitative analysis of the effects of a comorbid disordered gambling diagnosis with schizophrenia. <i>Schizophrenia Research</i> , 2016, 171, 50-55.	1.1	20
525	Testing the Identification/Production Hypothesis of Implicit Memory in Schizophrenia: The Role of Response Competition. <i>Journal of the International Neuropsychological Society</i> , 2016, 22, 314-321.	1.2	6
526	Effects of Blocking D2/D3 Receptors on Mismatch Negativity and P3a Amplitude of Initially Antipsychotic Na ⁺ -ve, First Episode Schizophrenia Patients. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, pyv109.	1.0	18
527	Subjective versus objective cognition: Evidence for poor metacognitive monitoring in schizophrenia. <i>Schizophrenia Research</i> , 2016, 178, 74-79.	1.1	39
528	The optimisation of experience sampling protocols in people with schizophrenia. <i>Psychiatry Research</i> , 2016, 244, 289-293.	1.7	32
529	The dynamics of attachment insecurity and paranoid thoughts: An experience sampling study. <i>Psychiatry Research</i> , 2016, 246, 32-38.	1.7	29
530	Effectiveness of rivastigmine on positive, negative, and cognitive symptoms of schizophrenia: a double-blind clinical trial. <i>Therapeutic Advances in Psychopharmacology</i> , 2016, 6, 308-316.	1.2	9
531	Î ² -hydroxybutyrate, pyruvate and metabolic profiles in patients with schizophrenia: A case control study. <i>Psychoneuroendocrinology</i> , 2016, 73, 1-8.	1.3	12
532	Machine-learning-based diagnosis of schizophrenia using combined sensor-level and source-level EEG features. <i>Schizophrenia Research</i> , 2016, 176, 314-319.	1.1	120
533	An optimal combination of MCCB and CANTAB to assess functional capacity in older individuals with schizophrenia. <i>International Journal of Geriatric Psychiatry</i> , 2016, 31, 1116-1123.	1.3	11
534	The relationship of depersonalization and absorption to hallucinations in psychotic and non-clinical participants. <i>Psychiatry Research</i> , 2016, 244, 357-362.	1.7	15
535	The communicative impairment as a core feature of schizophrenia: Frequency of pragmatic deficit, cognitive substrates, and relation with quality of life. <i>Comprehensive Psychiatry</i> , 2016, 71, 106-120.	1.5	108
536	Prevalence of and predictors for depression in individuals with schizophrenia. <i>European Neuropsychopharmacology</i> , 2016, 26, S497-S498.	0.3	1
537	High resolution examination of the role of sleep disturbance in predicting functioning and psychotic symptoms in schizophrenia: A novel experience sampling study.. <i>Journal of Abnormal Psychology</i> , 2016, 125, 788-797.	2.0	77

#	ARTICLE	IF	CITATIONS
538	Rapid detection of alteration of serum IgG in patients with schizophrenia after risperidone treatment by matrix-assisted laser desorption ionization/time-of-flight mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2016, 30, 2645-2649.	0.7	9
539	Gender Differences in Depressive Symptoms Among Inpatients. <i>Journal of Microbiology and Biotechnology</i> , 2016, 26, 248-256.	0.9	1
540	Culturally-adapted Family Intervention (CaFI) for African-Caribbeans diagnosed with schizophrenia and their families: a feasibility study protocol of implementation and acceptability. <i>Pilot and Feasibility Studies</i> , 2016, 2, 39.	0.5	27
541	The Phenomenology and Generation of Positive Mental Imagery in Early Psychosis. <i>Clinical Psychology and Psychotherapy</i> , 2016, 23, 523-532.	1.4	10
542	An Exploration of the Reliability and Validity of the Spanish Version of the "Voice and You"™ (VAY): A Scale for Measuring the Relationship with Voices. <i>Clinical Psychology and Psychotherapy</i> , 2016, 23, 183-188.	1.4	7
543	Perception of complexity, interest level, and preference for harmonic progression of music for adults with schizophrenia. <i>Arts in Psychotherapy</i> , 2016, 48, 1-7.	0.6	2
544	The influence of medical burden severity and cognition on functional competence in older community-dwelling individuals with schizophrenia. <i>Schizophrenia Research</i> , 2016, 170, 330-335.	1.1	19
545	Family Aided Community Treatment for the Treatment of Early Psychosis: A Proof of Concept Study. <i>Community Mental Health Journal</i> , 2016, 52, 623-630.	1.1	3
546	Profiling the psychotic, depressive and anxiety symptoms in chronic ketamine users. <i>Psychiatry Research</i> , 2016, 237, 311-315.	1.7	37
547	Elucidating the role of Early Maladaptive Schemas for psychotic symptomatology. <i>Psychiatry Research</i> , 2016, 238, 53-59.	1.7	19
548	Relationship between public and private self-focused attention and auditory verbal hallucinations as an interpersonal process. <i>Psychosis</i> , 2016, 8, 118-129.	0.4	4
549	Dissociation and mindfulness in patients with auditory verbal hallucinations. <i>Journal of Trauma and Dissociation</i> , 2016, 17, 294-306.	1.0	22
550	Subjective distress in a representative sample of outpatients with psychotic disorders. <i>Journal of Affective Disorders</i> , 2016, 189, 220-223.	2.0	8
551	Duration of untreated psychosis and acute remission of negative symptoms in a <sc>S</sc>outh <sc>A</sc>merican first-episode psychosis cohort. <i>Microbial Biotechnology</i> , 2017, 11, 77-82.	0.9	14
552	Predictors and mediators of trait anger across the psychosis continuum: The role of attachment style, paranoia and social cognition. <i>Psychiatry Research</i> , 2017, 249, 132-138.	1.7	8
553	A comparison of psychotic symptoms in subjects with methamphetamine versus cocaine dependence. <i>Psychopharmacology</i> , 2017, 234, 1535-1547.	1.5	23
554	Psychotic Depression and Suicidal Behavior. <i>Psychiatry (New York)</i> , 2017, 80, 17-29.	0.3	31
555	Add-on Antidepressants in the Naturalistic Treatment of Schizophrenia Spectrum Disorder "When, Who, and How?. <i>Pharmacopsychiatry</i> , 2017, 50, 136-144.	1.7	3

#	ARTICLE	IF	CITATIONS
556	The impact of an empowerment intervention on people with schizophrenia: Results of a randomized controlled trial. <i>International Journal of Social Psychiatry</i> , 2017, 63, 212-223.	1.6	21
557	Association between altered physical activity and neurocognitive function among people with schizophrenia: A minimum 6-months' follow-up study. <i>Comprehensive Psychiatry</i> , 2017, 77, 45-52.	1.5	10
558	A novel approach to measuring response and remission in schizophrenia in clinical trials. <i>Schizophrenia Research</i> , 2017, 190, 123-128.	1.1	6
559	Reduced white matter integrity and facial emotion perception in never-medicated patients with first-episode schizophrenia: A diffusion tensor imaging study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017, 77, 57-64.	2.5	12
560	Nicotine dependence is associated with depression and childhood trauma in smokers with schizophrenia: results from the FACE-SZ dataset. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2017, 267, 567-577.	1.8	21
561	Effect of Valerian in Preventing Neuropsychiatric Adverse Effects of Efavirenz in HIV-Positive Patients: A Pilot Randomized, Placebo-Controlled Clinical Trial. <i>Annals of Pharmacotherapy</i> , 2017, 51, 457-464.	0.9	17
562	Polygenic Risk Score associated with specific symptom dimensions in first-episode psychosis. <i>Schizophrenia Research</i> , 2017, 184, 116-121.	1.1	29
563	Could PANSS be a useful tool in the determining of the stages of schizophrenia? A clinically operational approach. <i>Journal of Psychiatric Research</i> , 2017, 86, 66-72.	1.5	21
564	Cost Utility Analysis. , 2017, , 89-119.		4
565	Differential Cortical Gray Matter Deficits in Adolescent- and Adult-Onset First-Episode Treatment-Naïve Patients with Schizophrenia. <i>Scientific Reports</i> , 2017, 7, 10267.	1.6	18
566	Rapid and simple analysis of disease-associated biomarkers of Taiwanese patients with schizophrenia using matrix-assisted laser desorption ionization mass spectrometry. <i>Clinica Chimica Acta</i> , 2017, 473, 75-81.	0.5	6
567	Gender differences in susceptibility to schizophrenia: Potential implication of neurosteroids. <i>Psychoneuroendocrinology</i> , 2017, 84, 87-93.	1.3	14
568	Stress sensitivity in paranoia: poor-me paranoia protects against the unpleasant effects of social stress. <i>Psychological Medicine</i> , 2017, 47, 2834-2843.	2.7	10
569	Validity of remission and recovery criteria for schizophrenia and major depression: comparison of the results of two one-year follow-up naturalistic studies. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2017, 267, 303-313.	1.8	8
570	Mindfulness as a Mediator Between the Relational Style with Voices and Negative Affect. <i>Mindfulness</i> , 2017, 8, 454-459.	1.6	4
571	Diabetes Knowledge Among Adults with Serious Mental Illness and Comorbid Diabetes Mellitus. <i>Archives of Psychiatric Nursing</i> , 2017, 31, 190-196.	0.7	7
572	Linguistic Markers Indicating Therapeutic Outcomes of Social Media Disclosures of Schizophrenia. <i>Proceedings of the ACM on Human-Computer Interaction</i> , 2017, 1, 1-27.	2.5	57
573	Possible Facilitative Effects of Repeated Anodal Transcranial Direct Current Stimulation on Functional Outcome 1 Month Later in Schizophrenia: An Open Trial. <i>Frontiers in Psychiatry</i> , 2017, 8, 184.	1.3	17

#	ARTICLE	IF	CITATIONS
574	Effect of Transcranial Direct Current Stimulation on Functional Capacity in Schizophrenia: A Study Protocol for a Randomized Controlled Trial. <i>Frontiers in Psychiatry</i> , 2017, 8, 233.	1.3	4
575	Neurological soft signs in Tunisian patients with first-episode psychosis and relation with cannabis use. <i>Annals of General Psychiatry</i> , 2017, 16, 30.	1.2	4
576	Correlations between physical activity and neurocognitive domain functions in patients with schizophrenia: a cross-sectional study. <i>BMC Psychiatry</i> , 2017, 17, 4.	1.1	13
577	Qualidade de vida de familiares de pacientes com esquizofrenia: Escala S-CGQoL. <i>Psicologia - Teoria E Prática</i> , 2017, 18, .	0.0	0
578	Neurocognitive differences between inpatients and outpatients with symptomatically nonremitted schizophrenia: A cross-sectional study. <i>Perspectives in Psychiatric Care</i> , 2018, 54, 501-506.	0.9	3
579	Effects of transcranial direct current stimulation on working memory and negative symptoms in schizophrenia: a phase II randomized sham-controlled trial. <i>Schizophrenia Research: Cognition</i> , 2018, 12, 20-28.	0.7	37
580	Hippocampal Network Modularity Is Associated With Relational Memory Dysfunction in Schizophrenia. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2018, 3, 423-432.	1.1	23
581	Neurocognitive Functions in Patients With Remitted and Nonremitted Schizophrenia: A Cross-Sectional Study. <i>Perspectives in Psychiatric Care</i> , 2018, 54, 25-30.	0.9	3
582	Increased serum levels of cysteine in patients with schizophrenia: A potential marker of cognitive function preservation. <i>Schizophrenia Research</i> , 2018, 192, 391-397.	1.1	20
583	Utilising symptom dimensions with diagnostic categories improves prediction of time to first remission in first-episode psychosis. <i>Schizophrenia Research</i> , 2018, 193, 391-398.	1.1	7
584	Monocausal attribution and its relationship with reasoning biases in schizophrenia. <i>Schizophrenia Research</i> , 2018, 193, 77-82.	1.1	23
585	Decreased value-sensitivity in schizophrenia. <i>Psychiatry Research</i> , 2018, 259, 295-301.	1.7	11
586	What could be learned from a decade with standardized remission criteria in schizophrenia spectrum disorders: An exploratory follow-up study. <i>Schizophrenia Research</i> , 2018, 195, 103-109.	1.1	11
587	Metacognitive training in patients recovering from a first psychosis: an experience sampling study testing treatment effects. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2018, 268, 57-64.	1.8	9
588	Affective and Cognitive Verbal Theory of Mind in Schizophrenia: Results From a Novel Paradigm. <i>Journal of the International Neuropsychological Society</i> , 2018, 24, 305-309.	1.2	5
589	Spousal Caregiver Burden and Its Relation with Disability in Schizophrenia. <i>Indian Journal of Psychological Medicine</i> , 2018, 40, 22-28.	0.6	21
590	Developing a dynamic model of anomalous experiences and function in young people with or without psychosis: a cross-sectional and longitudinal study protocol. <i>BMJ Open</i> , 2018, 8, e022546.	0.8	6
591	Activity Based Group Intervention in Improving Negative Symptoms and Functional Outcome in Patients with Chronic Schizophrenia in Welfare Homes. <i>Journal of Psychosocial Rehabilitation and Mental Health</i> , 2018, 5, 119-125.	0.4	2

#	ARTICLE	IF	CITATIONS
592	Economic evaluation of brief cognitive behavioural therapy for social activation in recent-onset psychosis. <i>PLoS ONE</i> , 2018, 13, e0206236.	1.1	8
593	The effect of obsessive compulsive symptoms on psychopathology in patients with schizophrenia. <i>Revista De Psiquiatria Clinica</i> , 2018, 45, 61-66.	0.6	4
594	Association Studies of HSPA1A and HSPA1L Gene Polymorphisms With Schizophrenia. <i>Archives of Medical Research</i> , 2018, 49, 342-349.	1.5	10
595	Relationship between social and cognitive functions in people with schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2018, Volume 14, 2215-2224.	1.0	15
596	Identifying improvable employment-related factors in schizophrenia patients. <i>Psychiatry Research</i> , 2018, 266, 199-205.	1.7	3
597	Need for information in a representative sample of outpatients with schizophrenia disorders. <i>International Journal of Social Psychiatry</i> , 2018, 64, 476-481.	1.6	23
598	Gender differences in schizophrenia: A multicentric study from three Latin-America countries. <i>Psychiatry Research</i> , 2018, 266, 65-71.	1.7	11
599	The effect of transcranial direct current stimulation on psychotic symptoms of schizophrenia is associated with oxy-hemoglobin concentrations in the brain as measured by near-infrared spectroscopy: A pilot study. <i>Journal of Psychiatric Research</i> , 2018, 103, 5-9.	1.5	11
600	Two case studies from a virtual reality intervention for delusions: feasibility and preliminary evidence. <i>The Cognitive Behaviour Therapist</i> , 2018, 11, .	0.4	4
601	Functional remission in schizophrenia: A FROGS-based definition and its convergent validity. <i>Psychiatry Research</i> , 2018, 268, 94-101.	1.7	8
602	Exploring the relationship between the anticipation and experience of pleasure in people with schizophrenia: An experience sampling study. <i>Schizophrenia Research</i> , 2018, 202, 72-79.	1.1	33
603	Synthetic Cannabinoid use in a Case Series of Patients with Psychosis Presenting to Acute Psychiatric Settings: Clinical Presentation and Management Issues. <i>Brain Sciences</i> , 2018, 8, 133.	1.1	37
604	Serum levels of β-hydroxybutyrate and pyruvate, metabolic changes and cognitive function in patients with schizophrenia during antipsychotic treatment: a preliminary study. <i>Neuropsychiatric Disease and Treatment</i> , 2018, Volume 14, 799-808.	1.0	4
605	Superior memory performance in healthy individuals with subclinical psychotic symptoms but without genetic load for schizophrenia. <i>Schizophrenia Research: Cognition</i> , 2018, 13, 7-11.	0.7	2
606	Olfactory impairment in first-episode schizophrenia: a case-control study, and sex dimorphism in the relationship between olfactory impairment and psychotic symptoms. <i>BMC Psychiatry</i> , 2018, 18, 199.	1.1	25
607	Amisulpride augmentation of clozapine for treatment-refractory schizophrenia: a double-blind, placebo-controlled trial. <i>Therapeutic Advances in Psychopharmacology</i> , 2018, 8, 185-197.	1.2	11
608	Dissociation of fractional anisotropy and resting-state functional connectivity alterations in antipsychotic-naïve first-episode schizophrenia. <i>Schizophrenia Research</i> , 2019, 204, 230-237.	1.1	6
609	Abnormalities of regional homogeneity and its correlation with clinical symptoms in Naïve patients with first-episode schizophrenia. <i>Brain Imaging and Behavior</i> , 2019, 13, 503-513.	1.1	37

#	ARTICLE	IF	CITATIONS
610	Secretagogin may not be a new neuroendocrine biomarker in schizophrenia while levels may reflect clinical severity. <i>Journal of Theoretical Social Psychology</i> , 2019, 29, 394-398.	1.2	1
611	Predictors of treatment satisfaction in antipsychotic-naïve and previously medicated patients with acute-phase psychosis. <i>Nordic Journal of Psychiatry</i> , 2019, 73, 349-356.	0.7	3
612	Prolactin, flupenthixol decanoate and first episode schizophrenia – clinical and laboratory correlates. <i>Metabolic Brain Disease</i> , 2019, 34, 1679-1687.	1.4	6
613	Investigation of a traumatic psychosis subgroup: a cluster analysis of an antipsychotic free cohort.. <i>Psychosis</i> , 2019, 11, 298-307.	0.4	4
614	Disrupted Habituation in the Early Stage of Psychosis. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2019, 4, 1004-1012.	1.1	21
615	Impaired relational memory in the early stage of psychosis. <i>Schizophrenia Research</i> , 2019, 212, 113-120.	1.1	21
616	Assessment and Obligatory Treatment of Violent and Sexually Violent Offenders. , 2019, , .		4
617	Subjective quality of life among patients with schizophrenia spectrum disorder and patients with major depressive disorder. <i>BMC Psychiatry</i> , 2019, 19, 267.	1.1	20
618	Bimodal distribution of tone-matching deficits indicates discrete pathophysiological entities within the syndrome of schizophrenia. <i>Translational Psychiatry</i> , 2019, 9, 221.	2.4	28
619	Clinical and Genetic Factors Associated with Resistance to Treatment in Patients with Schizophrenia: A Case-Control Study. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4753.	1.8	14
620	Staging of Schizophrenia With the Use of PANSS: An International Multi-Center Study. <i>International Journal of Neuropsychopharmacology</i> , 2019, 22, 681-697.	1.0	28
621	Remission in schizophrenia – What are we measuring? Comparing the consensus remission criteria to a CGI-based definition of remission and to remission in major depression. <i>Schizophrenia Research</i> , 2019, 209, 185-192.	1.1	5
622	The Prevalence of Suicide Attempts and Independent Demographic and Clinical Correlates among Chronic Schizophrenia Patients in Agricultural Areas of China. <i>Psychiatric Quarterly</i> , 2019, 90, 683-691.	1.1	6
623	A Quantitative Justification of Similarity in Placebo Response Between Adults and Adolescents With Acute Exacerbation of Schizophrenia in Clinical Trials. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 1046-1055.	2.3	6
624	Attenuated mismatch negativity in patients with first-episode antipsychotic-naive schizophrenia using a source-resolved method. <i>NeuroImage: Clinical</i> , 2019, 22, 101760.	1.4	10
625	The effect of mind-body and aerobic exercise on negative symptoms in schizophrenia: A meta-analysis. <i>Psychiatry Research</i> , 2019, 279, 295-305.	1.7	41
626	Effects of clonidine on MMN and P3a amplitude in schizophrenia patients on stable medication. <i>Neuropsychopharmacology</i> , 2019, 44, 1062-1067.	2.8	5
627	Measuring the Burden of Schizophrenia Using Clinician and Patient-Reported Measures: An Exploratory Analysis of Construct Validity. <i>Patient</i> , 2019, 12, 405-417.	1.1	6

#	ARTICLE	IF	CITATIONS
628	Neuromelanin-sensitive MRI as a noninvasive proxy measure of dopamine function in the human brain. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 5108-5117.	3.3	136
629	Persistent Post-Concussive Psychiatric Problems. , 2019, , 422-495.		0
630	Insight and Associated Factors among Patients with Schizophrenia in Mental Specialized Hospital, Ethiopia, 2018. Psychiatry Journal, 2019, 2019, 1-5.	0.7	7
631	A Proof-of-Concept Study Evaluating the Phosphodiesterase 10A Inhibitor PF-02545920 in the Adjunctive Treatment of Suboptimally Controlled Symptoms of Schizophrenia. Journal of Clinical Psychopharmacology, 2019, 39, 318-328.	0.7	14
632	Insomnia and suicidal ideation in nonaffective psychosis. Sleep, 2019, 42, .	0.6	32
633	Coping styles mediate the association between negative life events and subjective well-being in patients with non-affective psychotic disorders and their siblings. Psychiatry Research, 2019, 272, 296-303.	1.7	12
634	Investigation of sex differences in delusion-associated cognitive biases. Psychiatry Research, 2019, 272, 515-520.	1.7	9
635	Self-defining Memories Predict Engagement in Structured Activity in First Episode Psychosis, Independent of Neurocognition and Metacognition. Schizophrenia Bulletin, 2019, 45, 1081-1091.	2.3	10
636	Binge drinking: Prevalence, correlates, and expectancies of alcohol use among individuals with first-episode psychosis. Microbial Biotechnology, 2019, 13, 1136-1145.	0.9	8
637	Comparing Schizophrenia Patients With a Predicted High/Low Risk of Nonresponse Receiving Treatment with Ziprasidone and Haloperidol: A Randomized-Controlled Study. Pharmacopsychiatry, 2019, 52, 180-185.	1.7	0
638	The correlation between the quality of life and clinical variables among outpatients with schizophrenia. Psychiatry Research, 2019, 271, 39-45.	1.7	14
639	Tobacco smoking is associated with antipsychotic medication, physical aggressiveness, and alcohol use disorder in schizophrenia: results from the FACE-SZ national cohort. European Archives of Psychiatry and Clinical Neuroscience, 2019, 269, 449-457.	1.8	22
640	Determinants of quality of life among people diagnosed with schizophrenia at outpatient clinics. Perspectives in Psychiatric Care, 2019, 55, 30-39.	0.9	15
641	Do schizotypy dimensions reflect the symptoms of schizophrenia?. Australian and New Zealand Journal of Psychiatry, 2019, 53, 236-247.	1.3	30
642	Shame and the psychosis continuum: A systematic review of the literature. Psychology and Psychotherapy: Theory, Research and Practice, 2020, 93, 160-186.	1.3	15
643	Association of HSPA1B Polymorphisms with Paranoid Schizophrenia in a Polish Population. NeuroMolecular Medicine, 2020, 22, 159-169.	1.8	10
644	Serum d- and l-lactate, pyruvate and glucose levels in individuals with at-risk mental state and correlations with clinical symptoms. Microbial Biotechnology, 2020, 14, 410-417.	0.9	6
645	Data, diagnoses, and interventions addressing the nursing focus of delusion: A scoping review. Perspectives in Psychiatric Care, 2020, 56, 175-187.	0.9	5

#	ARTICLE	IF	CITATIONS
646	What happens with schizophrenia patients after their discharge from hospital? Results on outcome and treatment from a "cereal-world" 2-year follow-up trial. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 270, 661-671.	1.8	7
647	The relationship with the voices as a dialogical experience: The role of self-focused attention and dissociation. <i>Journal of Clinical Psychology</i> , 2020, 76, 549-558.	1.0	5
648	Evidence for prefrontal cortex hypofunctioning in schizophrenia through somatosensory evoked potentials. <i>Schizophrenia Research</i> , 2020, 215, 197-203.	1.1	9
649	Prediction of individual responses to electroconvulsive therapy in patients with schizophrenia: Machine learning analysis of resting-state electroencephalography. <i>Schizophrenia Research</i> , 2020, 216, 147-153.	1.1	13
650	Alterations in methionine to homocysteine ratio in individuals with first-episode psychosis and those with at-risk mental state. <i>Clinical Biochemistry</i> , 2020, 77, 48-53.	0.8	8
651	Psychometric properties of the DSM-5 Clinician-Rated Dimensions of Psychosis Symptom Severity. <i>Schizophrenia Research</i> , 2020, 216, 416-421.	1.1	11
652	Spatial Suppression and Sensitivity for Motion in Schizophrenia. <i>Schizophrenia Bulletin Open</i> , 2020, 1, .	0.9	9
653	Akzeptanz und Nebenwirkungen einer Virtuellen-Realitäts-Intervention bei Menschen mit Psychose und gesunden Kontrollprobanden. <i>Verhaltenstherapie</i> , 2020, , 1-11.	0.3	0
654	Physical Activity, Sleep-related Behaviors and Severity of Symptoms in Schizophrenia. <i>Psychiatry Research</i> , 2020, 294, 113489.	1.7	4
655	Medial temporal lobe cortical changes in response to exercise interventions in people with early psychosis: A randomized controlled trial. <i>Schizophrenia Research</i> , 2020, 223, 87-95.	1.1	9
656	A new sex-specific underlying mechanism for female schizophrenia: accelerated skewed X chromosome inactivation. <i>Biology of Sex Differences</i> , 2020, 11, 39.	1.8	7
657	<p></p>Clinical Validity of Subjective Clinical Prognosis in First Episode Psychosis Schizophrenia Patients: An Analysis of Data from the European First Episode Schizophrenia Trial (EUFEST) Study</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2020, Volume 16, 1279-1284.	1.0	0
658	Interleukin-8 gene variations and the susceptibility to schizophrenia. <i>Psychiatry Research</i> , 2020, 293, 113421.	1.7	8
659	<p></p>Transdermal Asenapine in Schizophrenia: A Systematic Review</p>. <i>Patient Preference and Adherence</i> , 2020, Volume 14, 1541-1551.	0.8	9
660	EEG Source Network for the Diagnosis of Schizophrenia and the Identification of Subtypes Based on Symptom Severity" A Machine Learning Approach. <i>Journal of Clinical Medicine</i> , 2020, 9, 3934.	1.0	16
661	Trauma and Suicide. <i>Journal of Nervous and Mental Disease</i> , 2020, 208, 431-434.	0.5	4
662	Feature optimization method for machine learning-based diagnosis of schizophrenia using magnetoencephalography. <i>Journal of Neuroscience Methods</i> , 2020, 338, 108688.	1.3	8
663	Parasympathetic activity as a potential biomarker of negative symptoms in patients with schizophrenia. <i>Asia-Pacific Psychiatry</i> , 2020, 12, e12392.	1.2	3

#	ARTICLE	IF	CITATIONS
665	Neurocognitive effects of atypical antipsychotics in patients with first-episode schizophrenia. <i>Nordic Journal of Psychiatry</i> , 2020, 74, 594-601.	0.7	4
666	Different response patterns in hallucinations and delusions to antipsychotic treatment. <i>Nordic Journal of Psychiatry</i> , 2020, 74, 497-504.	0.7	3
667	A Holistic Client Functioning Profile Comparison of People With Serious Mental Illness. <i>Journal of Counseling and Development</i> , 2020, 98, 3-16.	1.3	4
668	A randomized, double blind, sham-controlled trial of repetitive transcranial magnetic stimulation (rTMS) in the treatment of negative symptoms in schizophrenia. <i>Brain Stimulation</i> , 2020, 13, 840-849.	0.7	32
669	Assessment of Similarity in Antipsychotic Exposureâ€Response Relationships in Clinical Trials Between Adults and Adolescents With Acute Exacerbation of Schizophrenia. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 848-859.	1.0	5
670	Using virtual reality to explore differences in memory biases and cognitive insight in people with psychosis and healthy controls. <i>Psychiatry Research</i> , 2020, 285, 112787.	1.7	18
671	A single assessment with the Brief Adherence Rating Scale (BARS) discriminates responders to long-acting injectable antipsychotic treatment in patients with schizophrenia. <i>Schizophrenia Research</i> , 2020, 220, 92-97.	1.1	2
672	Discerning undifferentiated anxiety from syndromal anxiety in acute-phase schizophrenia. <i>Annals of General Psychiatry</i> , 2020, 19, 26.	1.2	7
673	Modeling psychological function in patients with schizophrenia with the PANSS: an international multi-center study. <i>CNS Spectrums</i> , 2021, 26, 290-298.	0.7	5
674	The Impact of Anticholinergic Burden on Functional Capacity in Persons With Schizophrenia Across the Adult Life Span. <i>Schizophrenia Bulletin</i> , 2021, 47, 249-257.	2.3	14
675	Electrocardiographic evaluation of the ventricular arrhythmia risk in patients with schizophrenia. <i>Anadolu Psikiyatri Dergisi</i> , 2021, 21, 1.	0.3	1
676	One-year randomized trial comparing virtual reality-assisted therapy to cognitiveâ€behavioral therapy for patients with treatment-resistant schizophrenia. <i>NPJ Schizophrenia</i> , 2021, 7, 9.	2.0	36
677	Facilitative Effects of Transcranial Direct Current Stimulation on Semantic Memory Examined by Text-Mining Analysis in Patients With Schizophrenia. <i>Frontiers in Neurology</i> , 2021, 12, 583027.	1.1	1
678	Mindfulness-based group therapy for in-patients with schizophrenia spectrum disorders â€ Feasibility, acceptability, and preliminary outcomes of a rater-blinded randomized controlled trial. <i>Schizophrenia Research</i> , 2021, 228, 134-144.	1.1	22
679	Factors associated with dropout at 2 years post-initiation of treatment in the first episode of schizophrenia. <i>South African Journal of Psychiatry</i> , 2021, 27, 1657.	0.2	1
680	Cognitive Enhancers in Schizophrenia: A Systematic Review and Meta-Analysis of Alpha-7 Nicotinic Acetylcholine Receptor Agonists for Cognitive Deficits and Negative Symptoms. <i>Frontiers in Psychiatry</i> , 2021, 12, 631589.	1.3	18
681	Efficacy and Safety of Multi-Session Transcranial Direct Current Stimulation on Social Cognition in Schizophrenia: A Study Protocol for an Open-Label, Single-Arm Trial. <i>Journal of Personalized Medicine</i> , 2021, 11, 317.	1.1	7
682	Relationship between social cognition, general cognition, and risk for suicide in individuals with a psychotic disorder. <i>Schizophrenia Research</i> , 2021, 231, 227-236.	1.1	8

#	ARTICLE	IF	CITATIONS
683	Effects of methylphenidate on sensory and sensorimotor gating of initially psychostimulant-naïve adult ADHD patients. <i>European Neuropsychopharmacology</i> , 2021, 46, 83-92.	0.3	4
684	Morphological alterations of the corpus callosum in antipsychotic-naïve first-episode schizophrenia before and 1-year after treatment. <i>Schizophrenia Research</i> , 2021, 231, 115-121.	1.1	5
685	Schizophrenia and <i>Bartonella</i> spp. Infection: A Pilot Case-Control Study. <i>Vector-Borne and Zoonotic Diseases</i> , 2021, 21, 413-421.	0.6	17
686	The relationship between conventional clinical assessments and momentary assessments of symptoms and functioning in schizophrenia spectrum disorders: A systematic review. <i>Schizophrenia Research</i> , 2021, 232, 11-27.	1.1	12
687	Effects of mild-intensity physical exercise on neurocognition in inpatients with schizophrenia: A pilot randomized controlled trial. <i>Perspectives in Psychiatric Care</i> , 2022, 58, 1037-1047.	0.9	9
688	Effects of methylphenidate on mismatch negativity and P3a amplitude of initially psychostimulant-naïve, adult ADHD patients. <i>Psychological Medicine</i> , 2021, , 1-9.	2.7	3
689	Gender, age at onset, and duration of being ill as predictors for the long-term course and outcome of schizophrenia: an international multicenter study. <i>CNS Spectrums</i> , 2022, 27, 716-723.	0.7	3
690	Individuals at ultra-high risk of psychosis and first-degree relatives of patients with schizophrenia experience impaired family functionality and social support deficit in comparison to healthy controls. <i>Comprehensive Psychiatry</i> , 2021, 109, 152263.	1.5	5
691	Contemporary psychiatric intervention for chronic schizophrenia patients incarcerated in a religious asylum in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 1620-1626.	0.8	2
692	Large-scale evaluation of the Positive and Negative Syndrome Scale (PANSS) symptom architecture in schizophrenia. <i>Asian Journal of Psychiatry</i> , 2021, 62, 102732.	0.9	29
693	Animal-Assisted Therapy in Middle-Aged and Older Patients With Schizophrenia: A Randomized Controlled Trial. <i>Frontiers in Psychiatry</i> , 2021, 12, 713623.	1.3	6
694	The role of attachment, coping style and reasons for substance use in substance users with psychosis. <i>Clinical Psychology and Psychotherapy</i> , 2022, 29, 725-732.	1.4	2
695	Effects of <i>Withania somnifera</i> (Ashwagandha) on Stress and the Stress-Related Neuropsychiatric Disorders Anxiety, Depression, and Insomnia. <i>Current Neuropharmacology</i> , 2021, 19, 1468-1495.	1.4	40
696	Differences in patterns of metabolic abnormality and metabolic syndrome between early-onset and adult-onset first-episode drug-naïve schizophrenia patients. <i>Psychoneuroendocrinology</i> , 2021, 132, 105344.	1.3	9
697	Effects of IPS plus cognitive remediation in early psychosis: 18-month functioning outcomes of a randomized controlled trial. <i>Schizophrenia Research</i> , 2021, 236, 115-122.	1.1	7
698	Anterior-posterior axis of hippocampal subfields across psychoses: A B-SNIP study. <i>Biomarkers in Neuropsychiatry</i> , 2021, 5, 100037.	0.7	5
699	Relationship Between Neural Cell Adhesion Molecule-1 and Cognitive Functioning in Schizophrenia Spectrum Disorder. <i>Indian Journal of Clinical Biochemistry</i> , 2022, 37, 494-498.	0.9	5
700	EPA guidance on assessment of negative symptoms in schizophrenia. <i>European Psychiatry</i> , 2021, 64, e23.	0.1	94

#	ARTICLE	IF	CITATIONS
701	Motor-related oscillatory activity in schizophrenia according to phase of illness and clinical symptom severity. <i>NeuroImage: Clinical</i> , 2021, 29, 102524.	1.4	12
702	Cultural Considerations for Schizophrenia Spectrum Disorders II: Assessment and Treatment. , 2020, , 381-401.		3
703	Investigation of Schizophrenia with Human Induced Pluripotent Stem Cells. <i>Advances in Neurobiology</i> , 2020, 25, 155-206.	1.3	11
704	Psychotic Continuum or Distinct Entities: Perspective from Psychopharmacology. , 1995, , 31-55.		16
705	Sleep disturbance and quality of life in clinically stable inpatients with schizophrenia in rural China. <i>Quality of Life Research</i> , 2020, 29, 2759-2768.	1.5	8
706	“With a little help from my friends” social predictors of clinical recovery in first-episode psychosis. <i>Psychiatry Research</i> , 2017, 255, 209-214.	1.7	33
707	Essential CNS Drug Development. , 2012, , .		3
708	Associations between P3a and P3b amplitudes and cognition in antipsychotic-naïve first-episode schizophrenia patients. <i>Psychological Medicine</i> , 2019, 49, 868-875.	2.7	18
709	Observation of Metabolic Changes in Chronic Schizophrenia After Neuroleptic Treatment by In Vivo Hydrogen Magnetic Resonance Spectroscopy. <i>Investigative Radiology</i> , 1996, 31, 345-352.	3.5	76
710	Critique of the Canadian Multicenter Placebo-Controlled Study of Risperidone and Haloperidol. <i>Journal of Clinical Psychopharmacology</i> , 1995, 15, 226-228.	0.7	5
711	Reply to Drs. Musser and Kirisci. <i>Journal of Clinical Psychopharmacology</i> , 1995, 15, 228-230.	0.7	9
712	Relationship of Psychiatric Experience and Interrater Reliability in Assessment of Negative Symptoms. <i>Journal of Nervous and Mental Disease</i> , 1999, 187, 316-318.	0.5	9
713	Posttraumatic Stress Disorder Symptoms Related to Psychosis and Acute Involuntary Hospitalization in Schizophrenic and Delusional Patients. <i>Journal of Nervous and Mental Disease</i> , 1999, 187, 343-352.	0.5	110
714	Schizotypal personality traits and social cognition are associated with childhood trauma exposure. <i>British Journal of Clinical Psychology</i> , 2018, 57, 397-419.	1.7	27
715	The cortical thickness phenotype of individuals with DISC1 translocation resembles schizophrenia. <i>Journal of Clinical Investigation</i> , 2015, 125, 3714-3722.	3.9	16
716	Placebo-Controlled Study of the D ₄ /5-HT _{2A} Antagonist Fananserin in the Treatment of Schizophrenia. <i>American Journal of Psychiatry</i> , 1999, 156, 419-425.	4.0	82
718	Use of primary care by middle aged and older persons with schizophrenia. <i>Primary Care and Community Psychiatry</i> , 2007, 11, 101-106.	0.4	3
719	A prospective study to explore the relationship between MTHFR C677T genotype, physiological folate levels, and postpartum psychopathology in at-risk women. <i>PLoS ONE</i> , 2020, 15, e0243936.	1.1	4

#	ARTICLE	IF	CITATIONS
720	Aspirin Inclusion in Antipsychotic Treatment on Severity of Symptoms in Schizophrenia: A Randomized Clinical Trial. Iranian Journal of Psychiatry and Behavioral Sciences, 2016, In Press, .	0.1	2
721	Paranoid schizophrenia versus schizoaffective disorder: Neuropsychological aspects. Srpski Arhiv Za Celokupno Lekarstvo, 2015, 143, 391-396.	0.1	3
722	PSYCHOMETRIC PROPERTIES OF THE BURDEN INVENTORY FOR RELATIVES OF PERSONS WITH PSYCHOTIC DISTURBANCES. Psychological Reports, 2008, 103, 323.	0.9	4
723	Prevalencia de la depresi3n en Espa±a: An±lisis de los ±ltimos 15 a±os. European Journal of Investigation in Health, Psychology and Education, 2015, 5, 267.	1.1	12
724	Comparing Copper Serum Level and Cognitive Functioning in Patients With Schizophrenia and Healthy Controls. Basic and Clinical Neuroscience, 2020, 11, 649-658.	0.3	7
725	Culturally adapted Family Intervention (CaFI) for African-Caribbean people diagnosed with schizophrenia and their families: a mixed-methods feasibility study of development, implementation and acceptability. Health Services and Delivery Research, 2018, 6, 1-316.	1.4	14
726	A systematic review, psychometric analysis and qualitative assessment of generic preference-based measures of health in mental health populations and the estimation of mapping functions from widely used specific measures. Health Technology Assessment, 2014, 18, vii-viii, xiii-xxv, 1-188.	1.3	179
727	Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness. Health Technology Assessment, 2017, 21, 1-56.	1.3	28
728	Psychological approaches to understanding and promoting recovery in psychosis and bipolar disorder: a mixed-methods approach. Programme Grants for Applied Research, 2016, 4, 1-272.	0.4	12
729	Double-Blind, Placebo-Controlled Study of the Efficacy of Reboxetine and Citalopram as Adjuncts to Atypical Antipsychotics for Negative Symptoms of Schizophrenia. Journal of Clinical Psychiatry, 2014, 75, 608-615.	1.1	15
730	Selective Serotonin Reuptake Inhibitor (SSRI) Add-On Therapy for the Negative Symptoms of Schizophrenia. Journal of Clinical Psychiatry, 2007, 68, 604-610.	1.1	86
731	Onset of action of atypical and typical antipsychotics in the treatment of acute psychosis. Journal of Research in Pharmacy Practice, 2013, 2, 138.	0.2	8
732	Increased brain-derived neurotrophic factor exon IV histone 3 lysine 9 dimethylation in patients with schizophrenia. Taiwanese Journal of Psychiatry, 2019, 33, 99.	0.1	2
733	Amphetamine Versus Non Amphetamine-Related First Episode Psychosis in Saudi Arabian Patients. Pharmacology & Pharmacy, 2011, 02, 101-108.	0.2	1
734	Adjunctive Memantine Therapy for Cognitive Impairment in Chronic Schizophrenia: A Placebo-Controlled Pilot Study. Psychiatry Investigation, 2012, 9, 166.	0.7	38
735	Aspirin Inclusion in Antipsychotic Treatment on Severity of Symptoms in Schizophrenia: A Randomized Clinical Trial. Iranian Journal of Psychiatry and Behavioral Sciences, 2016, 11, .	0.1	5
736	Estimating the minimum important difference for the questionnaire about the Process of Recovery (QPR): an anchor-based approach. Psychosis, 2021, 13, 220-230.	0.4	3
737	Tratamiento combinado de clozapina y litio para la esquizofrenia y el trastorno esquizoafectivo. European Psychiatry (Ed Espa±ola), 2000, 7, 310-313.	0.0	0

#	ARTICLE	IF	CITATIONS
738	Validación de la Escala Informatizada de Riesgo de Suicidio, un instrumento de red neural de retropropagación (CSRS-BP). <i>European Psychiatry</i> (Ed España), 2002, 9, 441-448.	0.0	0
739	Acute In-patient Setting. , 2004, , 307-334.		0
740	Antipsychotic Combination with Psychosocial Intervention on Outcome of Schizophrenia (ACPIOS): Rationale and Design of the Clinical Trial. <i>Clinical Schizophrenia and Related Psychoses</i> , 2007, 1, 185-192.	1.4	2
742	Health-related quality of life in Schizophrenia: the use of SF-36 direct and standardized scores.. <i>Cureus</i> , 2012, , .	0.2	2
744	Die Bedeutung des 5-HT ₂ -Rezeptor-Antagonismus für die Behandlung der Schizophrenie, unter spezieller Berücksichtigung der Minussymptomatik. , 1990, , 223-230.		3
745	Assessment of Negative Symptoms: Instruments and Evaluation Criteria. , 1991, , 52-70.		3
746	Psychometrie, Rating-Skalen, Evaluation. , 1992, , 131-159.		0
747	Combined serotonin 5-HT ₂ and dopamine D ₂ antagonism in the treatment of schizophrenia: clinical results with risperidone. <i>Aktuelle Probleme Der Schizophrenie</i> , 1993, , 325-331.	0.1	0
748	Rating Scales for Mental Disorders. , 1993, , 107-293.		0
749	Das Konzept der D ₂ /S ₂ -Antagonisten in der Therapie der Minussymptomatik. , 1994, , 201-205.		0
750	Definition, Diagnostik und Therapie schizophrener Minussymptomatik. , 1995, , 29-52.		0
751	Measures of Global Functioning. , 1995, , 453-467.		0
752	Mitigating Engulfment: Recovering From a First Episode of Psychosis. <i>Journal of Psychosocial Nursing and Mental Health Services</i> , 1996, 34, 40-44.	0.3	1
753	Levels of Recovery From Psychotic Disorders Chart. <i>Journal of Psychosocial Nursing and Mental Health Services</i> , 1998, 36, 31-37.	0.3	2
754	Medidas de anhedonia y respuestas hedónicas a la sacarosa en pacientes depresivos y esquizofrénicos en comparación con sujetos sanos. <i>European Psychiatry</i> (Ed España), 1999, 6, 88-96.	0.0	0
755	Low Dose Celecoxib Combined with Clozapine for Treatment of Schizophrenia: A Double Blind Randomized Clinical Trial. <i>International Journal of Travel Medicine and Global Health</i> , 2015, 3, 11-17.	0.1	0
756	Neural Correlates of the Preserved Inhibition of Return in Schizophrenia. <i>PLoS ONE</i> , 2015, 10, e0119521.	1.1	1
757	Relation of Verbal Memory Dysfunction with Type and Severity of Psychiatric Symptoms in Schizophrenic Patients. <i>Zahedan Journal of Researches in Medical Sciences</i> , 2018, 20, .	0.1	0

#	ARTICLE	IF	CITATIONS
758	Assessment of Violent and Sexually Violent Offenders. , 2019, , 67-101.		0
762	Characteristics of the corpus callosum in chronic schizophrenia treated with clozapine or risperidone and those never-treated. BMC Psychiatry, 2021, 21, 538.	1.1	5
763	The association between BDNF C270T genetic variants and smoking in patients with mental disorders and in healthy controls. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2022, 113, 110452.	2.5	2
766	Relationship of Change in Plasma Clozapine/N-desmethylclozapine Ratio with Cognitive Performance in Patients with Schizophrenia. Psychiatry Investigation, 2020, 17, 1158-1165.	0.7	7
767	Repetitive transcranial magnetic stimulation for hallucination in schizophrenia spectrum disorders: A meta-analysis. Neural Regeneration Research, 2013, 8, 2666-76.	1.6	14
768	The influence of neurocognitive deficits and symptoms on quality of life in schizophrenia. Journal of Psychiatry and Neuroscience, 1997, 22, 235-43.	1.4	65
769	Interrelations between psychiatric symptoms and drug-induced movement disorder. Journal of Psychiatry and Neuroscience, 2006, 31, 177-80.	1.4	13
770	Demographic and clinical correlates of substance abuse comorbidity in schizophrenia. Indian Journal of Psychiatry, 2004, 46, 135-9.	0.4	15
771	A comparative efficacy study of centbutindole and haloperidol in schizophrenia. Indian Journal of Psychiatry, 1999, 41, 325-8.	0.4	5
772	An open study of clozapine in the treatment of resistant schizophrenia. Indian Journal of Psychiatry, 1999, 41, 336-40.	0.4	10
773	The stability of symptoms and syndromes in chronic schizophrenic patients. Indian Journal of Psychiatry, 1992, 34, 133-9.	0.4	5
775	The Relationship between Obsessions and Compulsions and Negative and Positive Symptoms in Schizophrenia. Iranian Journal of Psychiatry, 2012, 7, 140-5.	0.4	8
776	Effects of needs-assessment-based psycho-education of schizophrenic patients' families on the severity of symptoms and relapse rate of patients. Iranian Journal of Nursing and Midwifery Research, 2014, 19, 558-63.	0.2	3
777	Study of the Effect of Memantine on Negative Sign in Patients with Schizophrenia and Schizoaffective Disorders. Iranian Journal of Pharmaceutical Research, 2018, 17, 122-129.	0.3	5
778	Validation of the Russian Version of the Positive and Negative Syndrome Scale (PANSS-Ru) and Normative Data. Innovations in Clinical Neuroscience, 2018, 15, 32-48.	0.1	10
779	Association of Candidate Single Nucleotide Polymorphisms Related to Candidate Genes in Patients With Schizophrenia. Basic and Clinical Neuroscience, 2020, 11, 595-608.	0.3	0
780	Blood brain barrier permeability increases with age in individuals with 22q11.2 deletion syndrome. World Journal of Biological Psychiatry, 2022, 23, 475-482.	1.3	2
781	Cognitive dysfunction in first-episode schizophrenia and its correlation with negative symptoms and insight. Industrial Psychiatry, 2021, 30, 310.	0.3	5

#	ARTICLE	IF	CITATIONS
782	Isobaric tags for relative and absolute quantitation in identifying proteins for clozapine treatment response in patients with schizophrenia: A preliminary study. <i>Taiwanese Journal of Psychiatry</i> , 2021, 35, 140.	0.1	0
783	Attentional engagement and inhibitory control according to positive and negative symptoms in schizophrenia: An emotional antisaccade task. <i>Schizophrenia Research</i> , 2022, 239, 142-150.	1.1	3
784	Association of Candidate Single Nucleotide Polymorphisms Related to Candidate Genes in Patients With Schizophrenia. <i>Basic and Clinical Neuroscience</i> , 2020, 11, 595-608.	0.3	2
785	Cognitive-Behavioral Social Skills Training for patients with late-life schizophrenia and the moderating effect of executive dysfunction. <i>Schizophrenia Research</i> , 2022, 239, 160-167.	1.1	5
786	ENHANCE: Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Adjunctive Pimavanserin for Schizophrenia in Patients With an Inadequate Response to Antipsychotic Treatment. <i>Schizophrenia Bulletin Open</i> , 2022, 3, .	0.9	4
787	Psychosocial functioning as a personal resource promoting a milder course of schizophrenia. <i>Journal of Psychiatric Research</i> , 2022, 148, 121-126.	1.5	4
788	Negative symptoms in First-Episode Schizophrenia related to morphometric alterations in orbitofrontal and superior temporal cortex: the OPTiMISE study. <i>Psychological Medicine</i> , 2023, 53, 3471-3479.	2.7	6
789	Akathisia and atypical antipsychotics: relation to suicidality, agitation and depression in a clinical trial. <i>Acta Neuropsychiatrica</i> , 2022, 34, 282-288.	1.0	2
790	A new aspect on the correlation of ten SNPs in MIR and their target genes in dopaminergic pathways in schizophrenia. <i>Bulletin of the National Research Centre</i> , 2022, 46, .	0.7	2
791	Patient-reported impact of symptoms in schizophrenia scale (PRISS): Development and validation. <i>Acta Psychiatrica Scandinavica</i> , 2022, 145, 640-655.	2.2	1
792	Validity and Reliability of the Staden Schizophrenia Anxiety Rating Scale. <i>Diagnostics</i> , 2022, 12, 831.	1.3	5
793	HSPB1 Gene Variants and Schizophrenia: A Case-Control Study in a Polish Population. <i>Disease Markers</i> , 2022, 2022, 1-9.	0.6	2
794	Adjuvant electroconvulsive therapy with antipsychotics is associated with improvement in auditory mismatch negativity in schizophrenia. <i>Psychiatry Research</i> , 2022, 311, 114484.	1.7	1
795	Symptom remission and functional outcome in an Egyptian sample of patients with schizophrenia. <i>Middle East Current Psychiatry</i> , 2021, 28, .	0.5	0
796	BST-1 as a serum protein biomarker involved in neutrophil infiltration in schizophrenia. <i>World Journal of Biological Psychiatry</i> , 2022, 23, 537-547.	1.3	4
797	An association study of the HSPA8 gene polymorphisms with schizophrenia in a Polish population. <i>Cell Stress and Chaperones</i> , 2022, 27, 71-82.	1.2	0
798	Trait Anhedonia in Schizophrenia: A Systematic Review and Comparative Meta-analysis. <i>Schizophrenia Bulletin</i> , 2022, 48, 335-346.	2.3	2
805	EEG coherence following acute and chronic clozapine in treatment-resistant schizophrenics. <i>Experimental and Clinical Psychopharmacology</i> , 2002, 10, 435-44.	1.3	5

#	ARTICLE	IF	CITATIONS
806	Latent state-trait structure of BPRS subscales in clinical high-risk state and first episode psychosis. <i>Scientific Reports</i> , 2022, 12, 6652.	1.6	2
807	Effect of cognitive insight on clinical insight from pre-morbid to early psychosis stages. <i>Psychiatry Research</i> , 2022, 313, 114613.	1.7	3
808	Evaluation of a Collaborative Care Program for Patients With Treatment-Resistant Schizophrenia: Protocol for a Multiple Case Study. <i>JMIR Research Protocols</i> , 2022, 11, e35336.	0.5	1
809	Analysis of selected polymorphisms in FOXP3 gene in a cohort of Egyptian patients with schizophrenia. <i>Journal of Genetic Engineering and Biotechnology</i> , 2022, 20, 83.	1.5	0
810	Muay Thai, Psychological Well-Being, and Cultivation of Combat-Relevant Affordances. <i>Philosophies</i> , 2022, 7, 65.	0.4	6
811	Transcranial Direct Current Stimulation on the Left Superior Temporal Sulcus Improves Social Cognition in Schizophrenia: An Open-Label Study. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	6
812	Toll-Like Receptor 4 Gene Polymorphisms and Susceptibility to Schizophrenia: A Case-Control Study. <i>Immunological Investigations</i> , 2022, 51, 2009-2024.	1.0	7
813	Relation between Frontal Pole volumes and cognitive insight in Schizophrenia. <i>Asian Journal of Psychiatry</i> , 2022, , 103204.	0.9	1
814	Mindfulness, cognitive fusion, and self-compassion in patients with schizophrenia spectrum disordersâ€”A cross-sectional study. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	8
815	Clinical correlates of regional gray matter volumes in schizophrenia: A structural magnetic resonance imaging study. <i>Industrial Psychiatry</i> , 2022, 31, 282.	0.3	0
816	Comparison of prolactin level, sexual function, body mass index, and liver function tests in patients using depot antipsychotics. <i>Cukurova Medical Journal</i> , 2022, 47, 1172-1178.	0.1	0
817	Testing the validity and reliability of the Chinese version of the Staden schizophrenia anxiety rating scale. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	1
818	Hippocampal network dysfunction in early psychosis: a 2-year longitudinal study. <i>Biological Psychiatry Global Open Science</i> , 2022, , .	1.0	0
819	Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine-resistant treatment-refractory schizophrenia: a 12-week randomized, double-blind, placebo-controlled trial. <i>Military Medical Research</i> , 2022, 9, .	1.9	11
820	Impaired sensorimotor gating in schizophrenia with deficit and with nondeficit syndrome. <i>Swiss Medical Weekly</i> , 0, , .	0.8	9
821	The Correlation of PANSS Scores and P100 Latency in Patients with Schizophrenia and Migraine Headache Using Visual Evoked Potentials (VEPS) According to Gender and Age. <i>Acta Informatica Medica</i> , 2022, 30, 318.	0.5	0
822	Relationship of serum homocysteine and vitamin D with positive, negative, and extrapyramidal symptoms in schizophrenia: a caseâ€”control study in Iran. <i>BMC Psychiatry</i> , 2022, 22, .	1.1	0
823	Shared decision-making interventions for people with mental health conditions. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	6

#	ARTICLE	IF	CITATIONS
825	The association between fear of COVID-19 and depression, anxiety, and psychosis among Lebanese chronic patients with schizophrenia: any moderating effect of spirituality?. <i>Croatian Medical Journal</i> , 2022, 63, 412-422.	0.2	0
826	Cross-sectional associations between adaptive functioning and social cognitive and neurocognitive functions in adolescents with first-episode, early-onset schizophrenia spectrum disorders. <i>Development and Psychopathology</i> , 2024, 36, 208-218.	1.4	0
827	Predicting aging trajectories of decline in brain volume, cortical thickness and fractional anisotropy in schizophrenia. , 2023, 9, .		5
828	The Association of the Oral Microbiota with the Effects of Acid Stress Induced by an Increase of Brain Lactate in Schizophrenia Patients. <i>Biomedicines</i> , 2023, 11, 240.	1.4	5
829	A retrospective case-control study of facial emotion recognition in male veterans with chronic schizophrenia and its correlation with interpersonal communication. <i>BMC Psychiatry</i> , 2023, 23, .	1.1	0
830	Differentiating people with schizophrenia from healthy controls in a developing Country: An evaluation of portable functional near infrared spectroscopy (fNIRS) as an adjunct diagnostic tool. <i>Frontiers in Psychiatry</i> , 0, 14, .	1.3	2
831	The impact of shadowboxing on the psychological well-being of professional martial artists. <i>Discover Psychology</i> , 2023, 3, .	0.4	2
833	Mechanisms of action and processes of yoga-based group intervention for inpatients with schizophrenia spectrum disordersâ€“A longitudinal qualitative study. <i>Frontiers in Psychiatry</i> , 0, 14, .	1.3	2
834	Joint crisis plans and crisis cards in inpatient psychiatric treatment. <i>Deutsches A&#x0308;rztblatt International</i> , 0, , .	0.6	1
835	Effect of Family Psychological Education Program on Positive and Negative Symptoms of Schizophrenic Patients: A Randomized Controlled Trial. <i>Jundishapur Journal of Chronic Disease Care</i> , 2023, 12, .	0.1	1
836	Investigating brain aging trajectory deviations in different brain regions of individuals with schizophrenia using multimodal magnetic resonance imaging and brain-age prediction: a multicenter study. <i>Translational Psychiatry</i> , 2023, 13, .	2.4	8
837	The Relationship between Motor Symptoms, Signs, and Parkinsonism with Facial Emotion Recognition Deficits in Individuals with 22q11.2 Deletion Syndrome at High Genetic Risk for Psychosis. <i>Acta Neurologica Scandinavica</i> , 2023, 2023, 1-10.	1.0	0
838	Metabolic biomarkers of risperidone-induced weight gain in drug-naïve patients with schizophrenia. <i>Frontiers in Psychiatry</i> , 0, 14, .	1.3	0